



Europäisches Patentamt
European Patent Office
Office européen des brevets

(11) Publication number:

0 007 614

B1

(12)

EUROPEAN PATENT SPECIFICATION

(45) Date of publication of patent specification: **26.01.83**

(51) Int. Cl.³: **A 61 K 31/40 //C07D487/04,**
C07C103/46, C07C103/737,
C07C103/19, C07C123/00,
C07C101/18, C07C129/12,
C07C121/417, (A61K31/40,
31/195), (A61K31/40, 31/22),
(A61K31/40, 31/275)

(21) Application number: **79102615.6**

(22) Date of filing: **24.07.79**

(54) An antibacterial composition of thienamycin-type compound and a dipeptidase inhibitor.

(30) Priority: **24.07.78 US 927213**
22.06.79 US 50232

(73) Proprietor: **MERCK & CO. INC.**
126, East Lincoln Avenue P.O. Box 2000
Rahway, New Jersey 07065 (US)

(43) Date of publication of application:
06.02.80 Bulletin 80/3

(72) Inventor: **Kahan, Frederick M.**
2022 Brookside Avenue
Scotch Plains, N.J. 07076 (US)
Inventor: **Kropp, Helmut**
18 Boyd Terrace
Kenilworth, N.J. 07033 (US)

(45) Publication of the grant of the patent:
26.01.83 Bulletin 83/4

(74) Representative: **Abitz, Walter, Dr.-Ing. et al,**
Abitz, Morf, Gritschneider P.O. Box 86 01 09
D-8000 München 86 (DE)

(84) Designated Contracting States:
AT BE CH DE FR GB IT LU NL SE

(56) References cited:
FR - A - 2 272 684

B1

4

14

0

007

614

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European patent convention).

0007 614

An antibacterial composition of thienamycin-type compound and a dipeptidase inhibitor

Introduction

French Patent 2,272,684 discloses the addition of specific unsaturated fatty acids to antibiotics, for instance to penicillin, in order to increase the antibacterial effect against resistant bacteria.

5 A new class of fused ring β -lactam antibiotics, including thienamycin and its semi-synthetic derivatives, epithienamycins, and olivamic acids, has recently been described. These compounds which will be defined more extensively below, are hereinafter referred to as the "thienamycin class of compounds". These compounds have a high level of antibacterial activity, but are subject to extensive metabolism by mammalian species.


10 The kidney was identified as the primary site of metabolism, and an enzyme was purified from renal extracts which catalyzed the inactivation of thienamycin by hydrolysis of the β -lactam. By such criteria as cytological localization, substrate specificity and susceptibility to enzyme inhibitors, this enzyme is very similar if not identical to a widely studied renal dipeptidase (E.C.3.4.13.11), also referred to in the literature as "dehydropeptidase-I". However, the β -lactamase activity is exhibited only toward the thienamycin class of compounds. Indeed, there exists no precedent example of the 15 mammalian metabolism via β -lactam cleavage of any representative of the classical β -lactam antibiotics, the penicillins and cephalosporins.

Detailed Description of the Invention: Thienamycins

20 The term "thienamycin class of compounds" is used to identify 6- and (optionally) 2-substituted pen-2-em-3-carboxylic acids and 1-carbadethia-pen-2-em-3-carboxylic acids or 1-azabicyclo [3.2.0]hept-2-ene-7-one-2-carboxylic acids.

Specific compounds particularly useful in this invention are represented structurally in the following formula I:


25



30

wherein X can be CH₂ or S; R² can be hydrogen; —S—CH₂CH₂NHR³, wherein R³ is hydrogen, acetyl, formimidoyl, acetimidoyl; —S(O)—CH=CHNHCOCH₃ and —S—CH=CHNHCOCH₃; and R⁶ is

35



40 wherein R⁷ is hydrogen, hydroxy or hydroxy-sulfonyloxy, or R⁶ is H. All possible stereoisomeric forms are included within the above structural definition.

All of these compounds within Formula I are described in the literature. When X is CH₂, and R² is SCH₂CH₂NH₂, and R⁶ is CH(OH)CH₃, the compound is known as thienamycin, an antibiotic produced by fermentation of *S. cattleya*, deposited as NRRL 8057 at Northern Regional Research Laboratories, U.S. Department of Agriculture, Peoria, Illinois, U.S.A., on November 18, 1974 described and claimed in

45 U.S. Patent 3,950,357, issued April 13, 1976. The N-substituted derivatives of thienamycin, i.e., in the formula I above wherein R³ is other than hydrogen, are disclosed and claimed in co-pending U.S. applications and their published foreign equivalents. The fermentation product N-acetyl thienamycin (R⁶ is CH(OH)CH₃, and R³ is acetyl), also called 924A, is claimed in Belgian Patent No. 848,346, issued May 16, 1977. The N-imidoyl derivatives are covered in Belgian Patent No. 848,545, issued May 20, 1977.

50 The unsaturated side chain-containing compound, also called N-acetyl-dehydrothienamycin or 924A₅ is a fermentation product of *S. cattleya*, NRRL 8057 claimed in U.S. Patent 4,162,323 issued July 24, 1979, and also in Belgian Patent No. 866,035, issued October 17, 1978. Epimeric forms of N-acetyl thienamycin, also called 890A, and 890A₃, as well as the desacetyl 890A, and desacetyl 890A₃, are disclosed, respectively in published French Patent 7634887 granted April 14, 1980 and Belgian Patent 848,349, issued May 16, 1977. Epimeric forms of the unsaturated thienamycin, also called 890A₂ and 890A₅ are claimed in published French Patent 7711891 granted April 20, 1977.

55 The 6-hydroxysulfonyloxyethyl-containing N-acetyl compounds, also called 890A₉ or 890A₁₀, are claimed respectively, in published French Patent 7,734,456, granted June 23, 1980 and published French Patent No. 7,734,457, granted March 3, 1980. Desacetyl analogues of 890A₉ and 890A₁₀ are claimed in DE—OS 28 05 701, and also in French Patent 7,803,666, granted May 5, 1980, and DE—OS 28 05 724, and also in French Appln. 7,803,667, filed February 9, 1978. Some of these latter compounds in the 890A₉ and 890A₁₀ series are also known as derivatives of olivamic acid (see Corbett

0007614

et al., *J. Chem. Soc. Chem. Commun.* 1977, No. 24, pp. 953-54). Compounds of the Formula I above when R² is hydrogen, also called descysteaminyl thienamycins, are claimed in French Patent 7814597 granted October 27, 1980, and also in Belgian Patent 867,227, issued November 20, 1978.

When R⁶ is hydrogen, and X is CH₂, these compounds are disclosed in Belgian Patent 860,962, 5 and in its published German equivalent Off. 2,751,624.1, filed November 18, 1977.

A thienamycin-type antibiotic in which R² is —SCH₂CH₂NHAc and R⁶ is C₂H₅, has been named PS-5 and is reported by K. Okaimura et al., *J. Antibiotics* 31 p. 480 (1978), see also Belgian Patent 865,578.

The compounds in which X is S, also called "penems", are described by R.B. Woodward in 10 "Recent Advances in the Chemistry of β -Lactam Antibiotics", J. Elks (Ed), The Chemical Society, London, 1977, p. 167; R.B. Woodward, Abstracts of Uppsala University 500 Years Symposium on Current Topics in Drug Research, Uppsala, Sweden, October 1971, 1977. *Acta. Pharm. Suecica*, Vol. 13, Supplement, p. 23, and U.S. Patent 4,070,477, issued January 24, 1978.

Particularly preferred members within the thienamycin class of compounds are the N-formimidoyl 15 and N-acetamidoyl derivatives of thienamycin. The crystalline form of N-formimidoyl thienamycin, which has recently been described, is also useful in the practice of this invention. An example illustrating a preferred way of making this compound follows:

Illustrative Example

20 N-Formimidoyl thienamycin, crystalline

Step A. Benzylformimidate hydrochloride

A 3 l. three-necked flask fitted with an addition funnel, overhead stirrer, and a reflux condenser, was charged with a mixture of benzyl alcohol (125 g., 1.15 mol) formamide (51 g., 1.12 mol) and anhydrous ether (1200 ml.). The mixture was stirred vigorously at room temperature (20—25°C) under 25 a nitrogen atmosphere and benzoyl chloride (157 g., 1.12 mol) in 50 ml. of anhydrous ether was added dropwise using the addition funnel. The addition required approximately 50 minutes.

The reaction mixture was stirred an additional 60 minutes at room temperature. The ether was removed by decantation and 300 ml. of acetic anhydride in 500 ml. of anhydrous ether was added. The mixture was stirred 30 minutes at room temperature. The precipitate was allowed to settle and the 30 ether-acetic anhydride was again removed by decantation. The solid was collected by filtration, washed with 500 ml. of ether and dried *in vacuo* over KOH at 25°C for 2 hrs. to give 130 g. (67%) of benzyl-formimidate hydrochloride as a white solid.

The product was assayed by NMR δ (DMSO) 5.7 (s, 2H, OCH_2), 7.5 (s, 5H, O), 9.0 (s, 1H, HC=N). The product is thermally unstable. It decomposes to formamide and benzyl chloride at 0°C and above. 35 However, no appreciable decomposition was detected on storage at —20°C for 2 months.

Step B. Derivatization of Thienamycin

Thienamycin (in the form of a 6 l. aqueous solution, pH = 6.5, concentrate from the fermentation broth, containing 28 g. thienamycin) was placed in a large beaker (12 l) and cooled to 0°C. The 40 beaker was equipped with a pH meter and an efficient high speed stirrer. The pH was raised to 8.5 by the careful addition of 3N KOH (KOH was added dropwise via syringe to the stirred solution). The solution was treated with 6 equivalents of solid benzyl formimidate hydrochloride (~100 g.) in portions while maintaining the pH at 8.5 ± 0.3 by the addition of 3N KOH (200 ml.) using a syringe. The addition required 3—5 min. The reaction mixture was stirred for 6 min. at 0°C and then assayed by liquid 45 chromatography to insure completion of the reaction. The solution was adjusted to pH 7 with 1N HCl. The volume of the reaction mixture was measured, and the solution was assayed by UV. The neutralized reaction mixture was concentrated to 15 g./l. on the reverse osmosis unit at <10°C. The volume of the concentrate was measured and the pH was adjusted to 7.2—7.4, if necessary. The concentrate was filtered through a medium porosity sintered glass funnel to remove any solids present after concentration. 50

Step C. Dowex 50W x 2 Chromatography

The concentrate (750—1000 ml., 15—20 g.) was applied to 0°C. to a precooled 18 l. column of Dowex 50W x 2 in the potassium cycle (200—400 mesh resin) and the column was eluted at 0—5°C 55 with distilled deionized water a flow rate of 90 ml/min. and a head pressure of 0—45 psig. Forerun fractions of 4 l., 2 l., and one l., were collected followed by 18 fractions of 450 ml. each, and one final fraction of 2 l. Each fraction was assayed by UV (1/100 dilution, NH₂OH extinction was omitted) and the total amount of NFT present in each fraction was calculated. The beginning and end 60 fractions were assayed for liquid chromatography purity and the desired rich cut fractions were combined. The pH of the combined rich cuts was determined by both pH meter and bromothymol blue indicating solutions and was adjusted to pH 7.2—7.4 if necessary. The combined rich cuts (3—4 l.) were then assayed by UV and the total formamidine content was determined, 15—16 g., 75% yield from the column. The rich cuts were concentrated on the reverse osmosis unit at <10°C as far as possible, then the concentration to 33 g./l. was completed on the circulatory evaporator at less than 65 28°C. A total volume of about 500 ml. concentrate was obtained.

0007 614

Step D. Crystallization of N-Formimidoyl Thienamycin

The concentrate from the previous step is adjusted to pH 7.3, if necessary, and N-formimidoyl thienamycin content assayed by UV, was about 85—90%. The concentrate was filtered through a sintered glass funnel (medium porosity) into a large Erlenmeyer flask. Five volumes (~2200 ml.) of 3A ethanol was filtered into the concentrate and the solution was stirred at room temperature for 10 minutes and at 0°C for 12—24 hrs.

5 The crystals were filtered by suction filtration and washed with 0.1 volume (~250 ml.) of 0°C 80% 3A ethanol followed by 1/25 volume (100 ml.) of 3A ethanol at room temperature. The crystals were dried *in vacuo* for 12—24 hrs. to give approximately a 40% overall yield of N-formimidoyl thienamycin (10—12 g.).

10 Analytical results on a 50 g. blend of N-formimidoyl thienamycin, prepared as above, are as follows:


15 C, theory 45.42%; found, 45.82%
 H, theory 6.03%; found, 5.72%
 N, theory 13.24%; found, 13.10%
 20 S, theory 10.10%; found, 10.14%

residue on ignition, predicted 0.5, found 0.47%, $[\alpha]_D^{25} = 89.4^\circ$, T.G. = 6.8%, UV λ_{max} 300 nm, E% = 328.

25 **Detailed Description of the Invention Dipeptidase Inhibitors**

The chemical substances which selectively inhibit the metabolism of the dipeptidase [E.C.3.4.13.11], also called "dipeptidase inhibitors", include chemical compounds which are Z-2-acylamino-3-monosubstituted propenobates having the following formula

30



40 wherein R⁹ and R¹⁰ are hydrocarbon radicals in the range respectively of 3—10 and 1—15 carbon atoms. In either of these hydrocarbon radicals R⁹ and R¹⁰, up to 6 hydrogens may be replaced by halogens, or a non-terminal methylene may be replaced by oxygen or sulfur, including oxidized forms of the latter.

45 A terminal hydrogen in R¹⁰ can also be replaced by a hydroxyl or thiol group, which may be acylated, such as with an alkanoyl acid of 1—8 carbon atoms, or carbamoylated, including alkyl and dialkyl carbamate derivatives; or the hydrogen can be replaced by an amino group, which may be derivatized as in an acylamino, ureido, amidino, guanidino, or alkyl or substituted alkyl amino group, including quaternary nitrogen groupings; or, alternatively, there may be replacement by acid groups such as carboxylic, phosphonic or sulfonic acid groups or esters or amides thereof, as well as cyano; or combinations thereof, such as a terminal amino acid grouping.

50 R⁹ is preferably a branched alkyl or cycloalkyl radical (C_{3—10}), with a limitation that the carbon adjacent to the carbonyl cannot be tertiary. R¹ is hydrogen, loweralkyl (C_{1—6}) or dialkylamino-alkyl (e.g. —CH₂CH₂N(C₂H₅)₂, —CH₂CH(CH₃)N(CH₃)₂).

55 Some of the compounds with formula II above have asymmetric forms. Racemic Z-2-(2,2-dimethylcyclopropanecarboxamido)-2-octenoic acid has been resolved. The activity resides in the dextrorotatory isomer, which has the S-configuration.

Within the definition of R⁹, the following sub-groups are included:

—R⁴

II A

60 wherein R⁴ is a straight, branched or cyclic hydrocarbon radical of 3—10 carbon atoms which may be substituted as specified above in the definition of R⁹;

—R⁵R¹¹

II B

65 wherein R⁵ is cycloalkyl of 3—6 carbon atoms and R¹¹ is either 1 or 2 alkyl substituents which may be

0007 614

joined to form another ring on the cycloalkyl group, or R⁵ and R¹¹ may be substituted as specified above in the definition of R⁹;

—R¹²R⁸

II C

5 wherein R¹² is an alkylene group of 1—3 carbon atoms and R⁸ is cycloalkyl of 3—6 carbon atoms which may be substituted as specified above in the definitions of R⁹ and R¹⁰;
 within these sub-groups, the following specific compounds are included:

// A: Z - 2 - isovaleramido - 2 - pentenoic acid; methyl Z - 2 - isovaleramido - 2 - butenoate; Z - 2 - isovaleramido - 2 - butenoic acid; Z - 2 - benzamido - 2 - butenoic acid; Z - 2 - (3,5,5 - trimethylhexanamido) - 2 - butenoic acid; Z - 2 - cyclobutanecarboxamido - 2 - butenoic acid; Z - 2 - cyclopropanecarboxamido - 2 - butenoic acid; Z - 2 - cyclopropanecarboxamido - 2 - pentenoic acid; Z - 2 - (3 - methylvaleramido) - 2 - butenoic acid; Z - 2 - cycloheptanecarboxamido - 2 - butenoic acid; Z - 2 - nonamido - 2 - butenoic acid; Z - 2 - cyclohexanecarboxamido - 2 - butenoic acid; Z - 2 - (4 - methylvaleramido) - 2 - butenoic acid; Z - 2 - t - butylacetamido - 2 - butenoic acid; Z - 2 - octanamido - 2 - butenoic acid; Z - 2 - butyramido - 2 - butenoic acid; Z - 2 - valeramido - 2 - butenoic acid; Z - 2 - valeramido - 2 - pentenoic acid; Z - 2 - cyclopentanecarboxamido - 2 - butenoic acid; Z - 2 - (6 - methylheptanamido) - 2 - butenoic acid; Z - 2 - hexanamido - 2 - butenoic acid; Z - 2 - (3,7 - dimethyloctanamido) - 2 - butenoic acid; Z - 2 - (3,7 - dimethyl - 6 - octenamido) - 2 - butenoic acid; Z - 2 - (5 - chlorovaleramido) - 2 - butenoic acid; Z - 2 - (3 - chlorobenzoylamido) - 2 - butenoic acid; Z - 2 - (2 - chlorobenzamido) - 2 - butenoic acid; Z - 2 - nonanamido - 2 - butenoic acid; Z - 2 - (6 - bromohexanamido) - 2 - butenoic acid; Z - 2 - (3,3 - dimethylpropenamido) - 2 - butenoic acid; Z - 2 - benzamido - 2 - cinnamic acid; Z - 2 - benzamido - 2 - pentenoic acid; Z - 2 - benzamido - 5 - methoxy - 2 - pentenoic acid; Z - 2 - benamido - 2 - hexenedioic acid; Z - 2 - isovaleramido - 2 - octenoic acid; Z - 2 - isovaleramido - 2 - cinnamic acid; Z - 2 - isovaleramido - 2 - hexenedioic acid; Z - 2 - cyclopropanecarboxamido - 2 - cinnamic acid; Z - 2 - cyclopropanecarboxamido - 2 - hexenedioic acid; Z - 2 - (5 - methoxy - 3 - methylvaleramido) - 2 - butenoic acid; Z - 2 - ethylthioacetamido - 2 - butenoic acid; Z - 2 - (2,2 - dichlorocyclopropane - carboxamido) - 2 - butenoic acid; Z - 2 - (2 - ethylhexanamido) - 2 - butenoic acid; Z - 2 - di - n - propyl - acetamido - 2 - butenoic acid;

30 // B: Z - 2 - (2,2 - dimethylcyclopropanecarboxamido) - 2 - butenoic acid; (+) - Z - 2 - (2,2 - dimethylcyclopropanecarboxamido) - 2 - butenoic acid; Z - 2 - (2,2 - dimethylcyclopropanecarboxamido) - 2 - pentenoic acid; Z - 2 - (2,2 - dimethylcyclopropanecarboxamido) - 2 - octenoic acid; Z - 2 - (2,2 - dimethylcyclopropanecarboxamido) - 2 - hexenoic acid; Z - 2 - (2,2 - dimethylcyclopropanecarboxamido) - 2 - cinnamic acid; Z - 2 - (2,2 - dimethylcyclopropanecarboxamido) - 5 - methoxy - 2 - pentenoic acid; Z - 2 - (2,2 - dimethylcyclopropanecarboxamido) - 4,4,4 - trifluoro - 2 - butenoic acid; Z - 2 - (2,2 - dimethylcyclopropanecarboxamido) - 3 - (2 - chlorophenyl)propenoic acid; Z - 2 - (2,2 - dimethylcyclopropane - carboxamido) - 2 - hexenedioic acid; Z - 2 - (2 - ethylcyclopropanecarboxamido) - 2 - butenoic acid; Z - 2 - (2,2 - diethylcyclopropanecarboxamido) - 2 - butenoic acid; Z - 2 - (2,2 - diethylcyclopropanecarboxamido) - 2 - pentenoic acid; Z - 2 - (2 - isopropyl - 2 - methylcyclopropanecarboxamido) - 2 - butenoic acid; Z - 2 - (2 - methylcyclohexanecarboxamido) - 2 - butenoic acid; Z - 5 - cyano - 2 - (2,2 - dimethylcyclopropanecarboxamido) - 2 - pentenoic acid; Z - 5 - (N,N - dimethyl - carbamoyl) - 2 - (2,2 - dimethylcyclopropanecarboxamido) - 2 - pentenoic acid; Z - 2 - (2,2 - dimethylcyclopropanecarboxamido) - 5 - methanesulfonyl - 2 - pentenoic acid; Z - 2 - (2,2 - dimethylcyclopropanecarboxamido) - 5 - ethoxy - carbonyl - 2 - pentenoic acid; Z - 2 - (2 - methylcyclopropanecarboxamido) - 2 - butenoic acid; methyl Z - 2 - (2,2 - dimethylcyclopropanecarboxamido) - 2 - butenoate; ethyl Z - 2 - (2,2 - dimethylcyclopropanecarboxamido) - 2 - butenoate; 2 - dimethylaminoethyl ester of Z - 2 - (2,2 - dimethylcyclopropane - carboxamido) - 2 - butenoic acid; 3 - diethylaminopropyl ester of Z - 2 - (2,2 - dimethylcyclopropane - carboxamido) - 2 - pentenoic acid; Z - 2 - (2,3 - dimethylcyclopropanecarboxamido) - 2 - butenoic acid; Z - 2 - (3,3 - dimethylcyclobutanecarboxamido) - 2 - butenoic acid; Z - 2 - (2 - spirocyclopentanecarboxamido) - 2 - butenoic acid; Z - 2 - (2 - t - butyl - 3,3 - dimethylcyclopropanecarboxamido) - 2 - butenoic acid; Z - 2 - (2,2 - dimethylcyclopropanecarboxamido) - 4 - methyl - 2 - pentenoic acid; Z - 2 - (2 - t - butylcyclopropanecarboxamido) - 2 - butenoic acid; Z - 2 - (2 - phenylcyclopropanecarboxamido) - 2 - butenoic acid; Z - 3 - cyclohexyl - 2 - (2,2 - dimethylcyclopropanecarboxamido)propenoic acid; Z - 5 - carboxy - 5 - (2,2 - dimethylcyclopropanecarboxamido) - 4 - pentenamidine; Z - 5 - dimethyl amino - 2 - (2,2 - dimethylcyclopropanecarboxamido) - 2 - pentenoic acid; Z - 3 - cyclopropyl - 2 - (2,2 - dimethylcyclopropanecarboxamido)propenoic acid; Z - 2 - (2,2 - dimethylcyclopropanecarboxamido) - 2,5 - hexadienoic acid; Z - 2 - (2,2 - dimethylcyclopropanecarboxamido) - 4 - phenyl - 2 - butenoic acid; Z - 2 - (2,2 - dimethylcyclopropanecarboxamido) - 6 - mercapto - 2 - hexanoic acid; Z - 2 - (2,2 - dimethylcyclopropanecarboxamido) - 5 - methylthio - 2 - pentenoic acid; Z - 2 - (2,2 - dimethylcyclopropanecarboxamido) - 5 - phosphono - 2 - pentenoic acid; Z - 2 - (2,2 - dimethylcyclopropanecarboxamido) - 2 - heptenoic acid; Z - 2 - (2,2 - dimethylcyclopropanecarboxamido) - 5 - phenyl - 2 - pentenoic acid; Z - 2 - (2,2 - dimethylcyclopropanecarboxamido) - 2 - nonenoic acid; Z - 2 - (2,2 - dimethylcyclopropanecarboxamido) - 2 - decenoic acid; Z - 2 - (2,2 - dimethylcyclopropanecarboxamido) - 2 - tri - decenoic acid; Z - 2 - (2,2 - dimethylcyclopropanecarboxamido) - 6 - methoxy - 2 - hexenoic acid (and 5-

0007614

methoxy - 2 - pentenoic acid); Z - 2 - (2,2 - dimethylcyclopropanecarboxamido) - 6 - methyl - 2 - heptenoic acid; Z - 4 - cyclohexyl - 2 - (2,2 - dimethylcyclopropanecarboxamido) - 2 - butenoic acid;

II C: Z - 2 - cyclobutylacetamido - 2 - butenoic acid; Z - 2 - cyclopentylacetamido - 2 - butenoic acid; Z - 2 - cyclohexylacetamido - 2 - butenoic acid; Z - 2 - (4 - cyclohexylbutyramido) - 2 - butenoic acid; Z - 2 - cyclopropylacetamido - 2 - butenoic acid; Z - 2 - cyclopropylacetamido - 2 - pentenoic acid; Z - 2 - (3 - cyclopentylpropionamido) - 2 - butenoic acid; Z - 2 - (3 - cyclohexylpropionamido) - 2 - butenoic acid; Z - 2 - (4 - (2 - thiienyl) - butyramido) - 2 - butenoic acid; Z - 2 - (4 - phenylbutyramido) - 2 - butenoic acid; Z - 2 - (D,L - α - lipoamido) - 2 - pentenoic acid; Z - 2 - (D,L - α - lipoamido) - 2 - cinnamic acid; Z - 2 - (3 - (2 - tetrahydrofuryl) - propionamido) - 2 - butenoic acid.

Particularly preferred substituents within the definition of R⁹ above include the 2,2-dimethylcyclopropyl and the 2,2-dichlorocyclopropyl groups.

Within the definition of R¹⁰, particularly preferred groups of compounds included N-alkyl (1-9 carbons) and N-methyl (1-9 carbons), having a terminal substituent which is a quaternary nitrogen, 15 amine derivative, or amino acid derived group.

By the term "quaternary nitrogen" is meant a tetrasubstituted or heteroaromatic nitrogen which is positively charged. An ammonium moiety, substituted with hydrocarbon groups having 1-7 carbon atoms, which can be the same or different, is significative.

By the term "amine derivative" is meant a group such as amino, acylamino, ureido, amidino, 20 guanidino and alkyl derivatives thereof.

By the term "amino acid derived group" is meant a moiety such as cysteinyl (—SCH₂CH(NH₂)COOH) or sarcosyl (—N(CH₃)CH₂COOH) in which a hydrogen joined to O, N or S of known amino acids is replaced.

Particularly preferred compounds from the most preferred groups of substituents of R⁹ and R are 25 those wherein R⁹ is 2,2-dimethylcyclopropyl or 2,2-dichlorocyclopropyl, and R¹⁰ is a hydrocarbon chain of 3 to 7 carbon atoms without a terminal substituent, or having a terminal substituent which is trimethylammonium, amidino, guanidino, 2-amino-2-carboxyethylthio, or ureido. Names of specific examples of these include:

Z-2-(2,2-dimethylcyclopropanecarboxamido)-8-trimethylammonium hydroxide-2-octenoic acid
30 inner salt;
Z-2-(2,2-dichlorocyclopropanecarboxamido)-8-trimethylammonium hydroxide-2-octenoic acid
inner salt;
Z-2-(2,2-dimethylcyclopropanecarboxamido)-8-amidino-2-octenoic acid;
Z-2-(2,2-dimethylcyclopropanecarboxamido)-8-guanidino-2-octenoic acid;
35 Z-2-(2,2-dimethylcyclopropanecarboxamido)-8-ureido-2-octenoic acid;
Z-8-(L-2-amino-2-carboxyethylthio)-2-(2,2-dimethylcyclopropanecarboxamido)-2-octenoic acid;
Z-2-(2,2-dimethylcyclopropanecarboxamido)-2-octenoic acid (racemic and dextrorotatory forms);
and Z-2-(2,2-dichlorocyclopropanecarboxamido)-2-octenoic acid.

The Z configuration (J.E. Blackwood et al., *J. Am. Chem. Soc.*, 90, p. 509 (1968)) is assigned to 40 the above compounds on the basis of their NMR spectra by analogy with the work of A. Srinavasan et al. [Tetrahedron Lett., 891 (1976)].

Although these compounds of Formula II, when R¹ is H, are described and named as the free acids, it will be apparent to one skilled in the art that various pharmaceutically acceptable derivatives such as alkali and alkaline earth metal, ammonium, or amine salts, or the like can be employed as 45 equivalents thereto. Salts such as the sodium, potassium, calcium, or tetramethylammonium salts are suitable.

Some of the compounds of Formula II are novel compounds which are claimed in published European Patent application 79 102 616.4, filed on July 24, 1979, and which do not form part of this invention.

50 In accordance with what is said above this invention is directed to an antibacterial composition characterized in that it contains a combination of a 6-substituted and optionally 2-substituted pen-2-em-3-carboxylic acid, a 1-carbadethia-pen-2-em-3-carboxylic acid or 1-azabicyclo[3.2.0]hept-2-ene-7-one-2-carboxylic acid and a dipeptidase (E.C.3.4.13.11) inhibitor, the weight ratio of the first named material to the dipeptidase inhibitor being within the range of 1:3 to 30:1.

55 Methods of Testing and Using the Invention

As noted, disposition studies with thienamycin, its natural analogs and its semi-synthetic derivatives have revealed a major metabolic degradation pathway of elimination in the various species examined (mouse, rat, dog, chimpanzee, Rhesus monkey). The extent of metabolism is reflected in low 60 urinary recovery and short plasma half-lives. The nature of this degradation was demonstrated to be lactam cleavage by the renal dipeptidase (E.C.3.4.13.11), described first by Bergmann, M. and Schleich, H., *Z. Physiol. Chem.*, 205 65 (1932); see also Greenstein, J. P. *Advances in Enzymology*, Vol. VIII, Wiley-Interscience, (1948), New York, and Campbell, B. J.; Lin, Y-C., Davis R. V. and Ballew, E., "The Purification and Properties of Particulate Renal Dipeptidase", *Biochim. Biophys. Acta.*, 118, 371 65 (1966).

0007 614

In order to demonstrate the ability of the compounds of Formula II to suppress the action of the renal dipeptidase enzyme, an *in vitro* screen procedure was followed. This measured the ability of compounds to inhibit hydrolysis of glycyldehydrophenylalanine (GDP) by a solubilized preparation of dipeptidase isolated from hog kidneys. The procedure is as follows: to a 1 ml. system containing 50 mM

5 "MOPS" (3-(N-morpholino)propanesulfonic acid) buffer, pH 7.1, is added 5 μ g of lyophilized enzyme, and the test compound at a final concentration of 0.1 mM. After a five minute incubation at 37°C, GDP is added to a final concentration of 0.05 mM. Incubation is continued for 10 minutes, at 37°C and hydrolysis of GDP is measured by the change in optical density with time at 275 nm. Inhibition of the enzyme is gauged by comparison to a standard run containing no inhibitor and is expressed as the 10 inhibitor binding constant, K_i . This is the concentration of the inhibitor which achieves 50% inhibition of enzyme.

The substrate GDP is employed in preference to thienamycin in this screen because it has a much higher maximal velocity of hydrolysis by renal dipeptidase, thereby reducing the amount of enzyme required. Both GDP and thienamycin have a similar affinity for renal dipeptidase; furthermore, K_i 's of 15 inhibitors tested have been identical for the two substrates.

In addition to this *in vitro* screen procedure, an *in vivo* screen was followed to measure the test compound's ability to inhibit metabolism as reflected by increase in urinary recovery of thienamycin from the mouse. The procedure involves co-administration of the test compound by the intravenous or 20 subcutaneous route at a dose-rate of 10—100 mg/kg, with 10 mg/kg thienamycin. Thienamycin recovery in the urine over a 4 hour period is then compared with its recovery in a control group to which the test compound was not co-administered.

Urinary recovery of thienamycin was measured in all cases with the use of a cylinder or disc diffusion assay, conducted in a manner described in U.S. Patent 3,950,357. This bioassay, with *Staphylococcus aureus* ATCC 6538 as the test organism, has a useful response range from 0.04 μ g/ml 25 to 3.0 μ g/ml.

The combination of the inhibitor and the thienamycin class compound can be in the form of a pharmaceutical composition containing the two compounds in a pharmaceutically acceptable carrier. The two can be employed in amounts so that the weight ratio of the thienamycin class compound to inhibitor is 1:3 to 30:1, and preferably 1:1 to 5:1.

30 The components can also be separately administered. For instance, the thienamycin class compound can be administered intramuscularly or intravenously in amounts of 1—100 mg/kg/day, preferably 1—20 mg/kg/day, or 1—5 mg/kg/day, in divided dosage forms, e.g., three or four times a day. The inhibitor can be separately administered, orally, intramuscularly, or IV, in amounts of 1—100 mg/kg/day, or preferably 1—30 mg/kg/day, or 1—5 mg/kg/day. The amounts of the two 35 components administered during one day ideally are within the ratio limits denoted above.

The most preferred dosage levels presently known to applicants is as a single dose, of two crystalline compounds, one being N-formimidoyl thienamycin and the other being (+) Z-2-(2,2-dimethylcyclopropanecarboxamido)-2-octenoic acid, co-administered in a sterile aqueous IV injection form (sodium salt), at a level of 150 mg. of the thienamycin and either 75 or 150 mg of the octenoic 40 acid. This dose is given to humans (each assumed to weigh about 80 kg.) from 1 to 4 times a day, or 2—8 mg/kg/day of the thienamycin class compound and 1—8 mg/kg-day of the inhibitor.

The components, whether administered separately or together are employed in pharmaceutically acceptable carriers such as conventional vehicles adapted for oral administration such as capsules, tablets, or liquid solutions or suspensions. The components separately or together, can also be dissolved in a vehicle adapted for administration by injection. Suitable formulations for oral use, may include diluents, granulating agents, preservatives, binders, flavoring agents, and coating agents. An example of an oral use composition is the combination of active ingredients, or the acid component alone, intermixed in the dry pulverulent state with gelatin, starch, magnesium stearate, and alginic acid, and pressed into a tablet.

45 50 As noted above, the presently known preferred method is parenteral administration of the thienamycin class compound and either co-parenteral administration or oral administration of the inhibitor compound.

Examples which illustrate this invention follow.

55

SECTION 1. EXAMPLES ILLUSTRATING ACTIVITY

Example 1

In Vitro Test Data







A 1 ml. system of 50 mM "MOPS" buffer, pH 7.1, is used. To this is added 5 μ g of the pig renal enzyme and an amount of the test compound to bring its final concentration to 0.1 mM. After a five 60 minute incubation at 37°C, an amount of GDP is added to bring its final concentration to 0.05 mM. The system is again incubated for 10 minutes, at 37°C. Hydrolysis of GDP is measured by its change in optical density with time at 275 nm. Inhibition of the enzyme is gauged by comparison to a standard run containing no inhibitor and is presented as percent inhibition. The K_i is a constant indicating the concentration of inhibitor necessary to produce 50% inhibition of enzyme. It is a calculated value 65 obtained from running multiple *in vitro* assays, as above, at concentrations resulting in inhibition below

0007614

and above the 50% inhibition point. The results are presented in Table I.

5








TABLE I

10	Compounds	$R^{10} - C(H) = C(COOH) - NHCOR^9$	R^{10}	R^9	% Inhibition at 10^{-4} M	K_I (μM)
15	1	CH_2CH_3			98	0.18
20	2*	CH_3			98	0.39
25	2a*	CH_3			100	0.12
30	2b*	CH_3				19.8
35	3	CH_3			92	1.7
40	4	CH_2CH_3			87	3.2
45	5	CH_3	$-CH_2CH(CH_3)CH_2C(CH_3)_3$		81	4.4
50	6	CH_3			83	4.6

65 *Compounds 2, 2a, and 2b are the racemic, dextrorotatory and levorotatory forms respectively.





0007614

TABLE I (Continued)

Dipeptidase Inhibitor	R^{10}	R^9	% Inhibition at 10^{-4} M	K_I (μM)
7	CH ₃		91	6
8	CH ₃		80	6.2
9	CH ₃	$-CH_2-$ 	83	6.6
10	CH ₃		97	9
11	CH ₃	$-CH_2-CH(CH_3)-CH_2CH_3$	82	10
12	$-(CH_2)_4CH_2$			.03
13	$-(CH_2)_5N^+(CH_3)_3$			
14	$-(CH_2)_5N^+(CH_3)_3$			1.11
15	$-(CH_2)_5-NH-C=NH$			
16	$-(CH_2)_5-NH-C-N^+(CH_3)_2$			









0007614

TABLE I (Continued)

Dipeptidase Inhibitor	R ¹⁰	R ⁹	% Inhibition at 10 ⁻⁴ M	K _i (μM)
17	CH ₃	-CH ₂ C(CH ₃) ₃	75	20
18	CH ₃	-(CH ₂) ₆ CH ₃	72	26
19	CH ₃	-(CH ₂) ₂ CH ₃	69	30
20	CH ₃	-(CH ₂) ₃ - 	68	30
21	CH ₃	-CH ₂ - 	64	22
22	CH ₃	(CH ₂) ₃ CH ₃	64	32
23	CH ₃		59	30
24	CH ₃	-(CH ₂) ₄ CH(CH ₃) ₂	57	
25	CH ₃	-CH ₂ CH ₂ - 	56	
26	CH ₃	-CH ₂ CH ₂ - 	54	
27	CH ₃	-CH ₂ -(CH ₂) ₃ CH ₃	54	39
28	CH ₃	-(CH ₂) ₅ CH ₃	49	
29	CH ₃	-CH(CH ₂ CH ₃)CH ₂ CH ₂ CH ₂ CH ₃	33	
30	CH ₃	-CH(CH ₂ CH ₂ CH ₃) ₂	13	
31	CH ₃	-CH(CH ₃) ₂	31	
32	HOO-CH ₂ CH ₂		90	5
33	CH ₃	-CH ₂ -CH(CH ₃) ₂ CH ₂ OCH ₃	88	9













0007614

TABLE I (Continued)

Dipeptidase Inhibitor	R^{10}	R^9	% Inhibition at 10^{-4} M	K_i (μM)
34	CH ₃	CH ₂ CH ₂ CH ₂ CH ₂ CH ₂ Br	70	19
35	CH ₃	CH ₂ CH ₂ CH ₂ CH ₂ Cl	64	20
36	CH ₃	CH ₂ CH ₂ CH ₂ — 	72	11
37	CH ₃		90	6.5
38	CH ₃ (CH ₂) ₄	CH ₂ —CH(CH ₃) ₂	95	2.6
39	CH ₃		100	0.45
40	(CH ₃) ₂ CH		98	0.54
41	CH ₃		98	0.86
42	CH ₃		96	1.6
43	CH ₃		95	3
44	CH ₃ CH ₂		98	0.18
45	Ph		100	0.62











0007614

TABLE I (Continued)

Dipeptidase Inhibitor	R^{10}	R^9	% Inhibition at 10^{-4} M	K_I (μM)
46	$CH_3CH_2CH_2$		98	0.11
47			97	0.23
48	$CH_3(CH_2)_3$		100	0.11
49	$CH_3(CH_2)_4$		100	0.17
50	$HOOCH_2CH_2$		98	0.145
51			100	0.15
52	$PhCH_2CH_2$		96	0.33
53	$CH_3SCH_2CH_2$		99	0.12
54	$CH_3SO_2CH_2CH_2$		96	0.5
55	$CH_3(CH_2)_5$		98	0.149

0007614

TABLE I (Continued)

Dipeptidase Inhibitor	R^{10}	R^9	% Inhibition at 10^{-4} M	K_i (μM)
56	$CH_3(CH_2)_6$		99	0.092
57	$CH_3(CH_2)_9$		96	0.14
58	$PhCH_2$		98	0.44
59	$CH_3O(CH_2)_3$			0.28
60	$CH_3OCH_2CH_2$		98	0.32
61	$(CH_3)_3CCH_2$			0.34
62	$(CH_3)_2CHCH_2CH_2$		98	0.15
63	$H_2OC(CH_2)_3$		99	0.048
64				0.39

0007 614**Example 2*****In Vivo Test Data***

An *in vivo* assay on the mouse was conducted as follows: 20 g Charles River CD, female mice were injected subcutaneously with the chosen dose of the chemical inhibitor. About two minutes later, 5 the dose of thienamycin was given intravenously. A control of thienamycin above was also conducted. The level of thienamycin in the urine as a % of the dose was measured using a bioassay technique. Results are found in Table II. The two test compound numbers are those from Table I. Compound 7 is 2-isovaleramido-2-butenoic acid; compound 10 is Z-2-cyclopropylcarboxamido-2-butenoic acid.

10

TABLE II

15	Compound	Dose, mg /kg Compound	Dose, mg /kg Thienamycin	% Urinary Recovery of Thienamycin
20	7	50	10	53
25	7	10	10	63
	10	50	10	56
	Control	—	10	25 – 30

Example 3

The compounds 2-isovaleramido-2-butenoic acid, Compound 7, and Z-2-(2,2-dimethylcyclo-30 propanecarboxamido)-2-butenoic acid, Compound 2, were studied, in more detail *in vivo* in combination with thienamycin (THM), in the mouse. The general test procedure was similar to that of Example 2. Results are summarized in Table III and Table IV.

35 In another mouse study, the systemic anti-bacterial activity of thienamycin was enhanced approximately three-fold by coadministering 2-isovaleramido-2-butenoic acid, see Table V.

40

TABLE V

Effect of Co-administered 2-Isovaleramido-2-butanoic acid
on the Systemic Efficacy of Thienamycin on the Treatment
of *Staphylococcus aureus* Infections

45

ED ₅₀ , mg /kg		
THM	Alone	0.2
	+ 100 mg /kg inhibitor	0.06

55

60

65

0007614

TABLE III

Effect of Co-administered 2-Isovaleramidobutenoic Acid (Compound 7) on the Urinary Recovery of Thienamycin in the Mouse (a)

Route (b) Compound 7	THM	mg /kg Dose		Urinary Recovery of THM, %
		Compound 7	THM	
—	IV or SC	—	10	30 ± 5
SC	SC	0.3	10	33
SC	IV	2	10	42
SC	SC	2	10	47
SC	IV	10	10	53
SC	SC	50	10	54
SC	IV	50	10	53
SC	SC	80	10	59
SC	SC	100	10	81

(a) 20 g Charles River, CD₁ female mice.

(b) Co-administered.

TABLE IV

Effect of Co-administered Z-2-(2,2-Dimethylcyclopropane-carboxamido)-butenoic acid (Compound 2) on Urinary Recovery of Thienamycin in the Mouse (a)

Route (b) Compound 2	THM	mg /kg Dose		Urinary Recovery THM, %
		Compound %	THM	
—	SC	—	10 ¹	30 ± 5
SC	SC	0.1	10	35
SC	SC	0.3	10	40
SC	SC	1	10	46
SC	SC	10	10	60
SC	SC	10	10	73

(a) 20 g Charles River, CD₁ female mice.

(b) Co-administered.

0007614

Example 5

5 A male beagle was used for a study of the effect of dipeptidase inhibitors on the urinary recovery of N-formimidoyl thienamycin. In a control study, the dog was given 5 mg/kg IV of the N-formimidoyl thienamycin without inhibitor. A second experiment used the same amount of N-formimidoyl thienamycin, but also administered Z-2-isovaleramido-2-butenoic acid in 3 doses, each providing 20 mg/kg of the compound. The first dose was administered just after injection of the N-formimidoyl thienamycin, the second at 40 min. and the third at 60 min. The third study employed a single dose (2 mg/kg) of Z-2-(2,2-dimethylcyclopropanecarboxamido)-2-butenoic acid, administered just before injection of the N-formimidoyl thienamycin. The results are in Table VI.

10


TABLE VI

15 Urinary Recovery 3 Hours following the Administration of
N-formimidoylthienamycin (5 mg/kg IV) in a Male Beagle

	Test Compound	% Urinary Recovery
20	N-formimidoyl thienamycin	7.8
25	plus Z-2-isovaleramido-2-butenoic acid	46
30	plus Z-2-(2,2-dimethylcyclopropane carboxamido)-2-butenoic acid	53


SECTION 2. EXAMPLES ILLUSTRATING CHEMICAL PREPARATIONS

30 The inhibitor compounds are novel compounds claimed in a copending application. These compounds are made by condensing directly the appropriate 2-keto acid and amide:




40 wherein R⁹ and R¹⁰ are as defined. The general reaction conditions involve mixing approximately 1—4:1 parts of the acid to the amide in an inert solvent such as toluene or methyl isovalerate and heating at reflux with azeotropic removal of water for from 3—48 hours, preferably 5—24 hours. The solution when cooled normally yields the product in crystalline form, but the product can also be isolated using a base extraction process. The product can be recrystallized by using generally known techniques. An optional modification of this procedure requires an additional small amount of p-toluenesulfonic acid as catalyst during the reaction.

45 Another route to the novel inhibitor compounds uses an α -amino acid t-butyl ester in reaction with an acid chloride.



55 This reaction takes place in the presence of base, such as triethylamine, in a solvent such as methylene chloride. The resulting N-acylated product (VI) is then oxidized by treatment with t-butyl hypochlorite followed by addition of sodium methoxide. This yields the 2-methoxy derivative (VIII) and/or its elimination product, the α,β -unsaturated ester (IX). Further treatment with anhydrous hydrochloric acid converts either VIII or IX (or the mixture of both) to the desired α,β -unsaturated free acid (III).

0007614



10 Some compounds wherein R^{10} has a terminal substituent which is an amino, quaternary nitrogen, thiol or carboxyl, derivative can be made most conveniently from an intermediate having a bromo substituent instead of the desired terminal substituent, followed by condensation with the desired thiol, amino, acid, or the like.

15 More detail about preparation of the compounds is found in the following examples.

Example 6

Z-2-Isovaleramido-2-butenoic Acid

20 A solution of 1.07 g (10.5 mmole) of 2-keto-butyric acid and 0.71 g (7.0 mmole) of isovaleramide in 15 ml of toluene was stirred under reflux with collection of H_2O in a small Dean-Stark trap. After 5 hrs, the solution was cooled, resulting in fairly heavy crystallization. After standing, the solid was collected on a filter and washed with toluene and then with CH_2Cl_2 . Yield of white 25 crystals = 0.47 g, mp 172—174° (slight prelim. softening). The material was recrystallized from diisopropyl ketone. Tlc (4:1 toluene-AcOH) now showed only a faint trace of the other isomer. Yield of white crystals = 0.32 g (25%), mp 175° (slight prelim. softening). NMR indicated essentially exclusively Z-isomer.

	Anal. ($\text{C}_9\text{H}_{15}\text{NO}_3$)	Calcd.	Found
30	C	58.36	58.59
	H	8.16	8.55
	N	7.56	7.43

35

Example 7

Z-2-(2,2-Dimethylcyclopropanecarboxamido)-2-pentenoic acid

40 A solution of 1.74 g (15 mmole) of 2-keto-valeric acid and 1.13 g (10 mmole) of 2,2-dimethylcyclopropanecarboxamide in 20 ml of toluene was refluxed with stirring with collection of H_2O in a small Dean-Stark trap. After 20 hrs. the solution was cooled and treated with a gentle stream of N_2 . Before much of the solvent had evaporated, crystallization was induced by scratching. After standing, the solid was collected on a filter and washed with toluene and some Et_2O . Yield of white 45 crystals = 0.63 g (30%), mp 154.5—155.5° (slight prelim. softening). Tlc (4:1 toluene-AcOH) showed only an extremely faint trace of the other isomer. NMR was consistent with the Z-configuration.

	Anal. ($\text{C}_{11}\text{H}_{17}\text{NO}_3$)	Calcd.	Found
50	C	62.53	62.86
	H	8.11	8.27
	N	6.63	6.75

55

Example 8

Z-2-(3-Cyclopentylpropionamido)-2-butenoic acid

60 A solution of 1.41 g (10 mmole) of 3-cyclopentylpropionamide and 1.53 g (15 mmole) of 2-keto-butyric acid was stirred and refluxed under a small Dean-Stark trap. After 8 hrs. the solution was cooled, resulting in heavy crystallization. The solid was collected on a filter and washed with toluene and CH_2Cl_2 . Yield of white crystals = 1.44 g, mp 180.5—182° (prelim. softening). The material was recrystallized from methyl ethyl ketone. Yield of white needles = 0.63 g (28%), mp 184—185° (slight prelim. softening). Tlc (4:1 toluene-AcOH) now showed a single spot, and NMR indicated essentially pure Z-isomer.

65

0007 614

	Anal. (C ₁₂ H ₁₉ NO ₃)	Calcd.	Found
5	C	63.97	63.99
10	H	8.50	8.67
15	N	6.22	6.27

Example 9

10 Z-2-(2-Ethylhexanamido)-2-butenoic acid
 10 g. of 2-ethylhexanoyl chloride was added dropwise with stirring to 25 ml of cold conc. NH₄OH solution, resulting in immediate precipitation. The mixture was allowed to stir for 2 hrs., then filtered, and air dried to give 6.5 g. of amide. 1.4 g (10 mmole) of the above compound and 1.5 g of ketobutyric acid (15 mmole) were refluxed in 25 ml toluene for 15 hrs. with removal of water. The reaction mixture was cooled and partly evaporated with a stream of N₂. Crystallization of product occurred after standing for 3 hrs. The crystals were collected, washed 3x with toluene, and air dried. There were isolated 1.13 g (50%) of product, mp 160—162°. NMR was in accord with the assigned structure and indicated <5% E isomer. Tlc (4:1 toluene-AcOH) showed a single spot.

	Anal. (C ₁₂ H ₂₁ NO ₃)	Calcd.	Found
20	C	63.40	63.63
25	H	9.30	9.43
	N	6.16	5.88

Example 10

30 Z-2-(2,2-Dimethylcyclopropanecarboxamido)-2-butenoic acid
 1.53 g (15 mmoles) of 2-ketobutyric acid, 1.13 g (10 mmoles) of 2,2-dimethylcyclopropane-carboxamide and 20 ml of toluene stirred at reflux for 10 hours. After cooling the crystalline solid was filtered and washed with toluene (3 x 10 ml) and dried to give 1.06 g of product, mp 140—141°C. Tlc (4:1 toluene-AcOH) showed essentially one spot and the NMR spectrum fit the desired structure.
 35 Recrystallization from EtOAc gave after drying 0.533 g of product mp 142—143.5°, homogenous by tlc.

	Anal. (C ₁₀ H ₁₅ NO ₃)	Calcd.	Found
40	C	60.90	60.92
	H	7.67	7.71
	N	7.10	7.38

45 Example 11

Z-2-(2,2-Dimethylcyclopropanecarboxamido)-2-hexenedioic acid
 A mixture of 1.0 g of 2,2-dimethylcyclopropanecarboxamide, 2.4 g. of 2-keto adipic acid and 25 ml. of methyl isovalerate was heated under reflux for 4 hrs, with removal of H₂O by a modified Dean-Stark trap containing molecular sieves (4A). After standing at room temperature overnight, the crystalline precipitate was filtered, washed with ether and recrystallized from ethyl acetate to give 0.23 g. of product, m.p. 163—165°. The NMR spectrum was consistent with the desired structure.

	Anal. (C ₁₂ H ₁₇ NO ₅)	Calcd.	Found
55	C	56.46	56.20
	H	6.71	6.83
60	N	5.49	5.32

Example 12

Z-2-(2,2-Diethylcyclopropanecarboxamido)-2-butenoic acid
 A mixture of 2.3 g of 2-ketobutyric acid, 2.0 g of 2,2-diethylcyclopropanecarboxamide, and 25 ml of toluene was heated under reflux for 16 hours with removal of H₂O by a modified Dean-Stark trap containing molecular sieves (4A). No product precipitated upon cooling. Ether (25 ml) was added and

0 007 614

the mixture was extracted with saturated NaHCO_3 (3 times). The combined extracts were acidified with concentrated HCl. The gummy precipitate crystallized when triturated with water. Recrystallization from ethyl acetate gave 0.31 g of product, m.p. 129—30°. The NMR spectrum was consistent with the desired structure.

5	Anal. ($\text{C}_{12}\text{H}_{19}\text{NO}_3$)	Calcd.	Found
	C	63.98	64.01
10	H	8.50	8.62
	N	6.22	6.21

Example 13

15 2-(2,2-Dimethylcyclopropanecarboxamido)-2-hexanoic acid

Step A: *DL*-Norleucine *t*-butyl ester

General procedure of R. Roeske, *J. Org. Chem.* 28, p. 1251 (1963).

To a suspension of 9.82 g (75 mmole) of *DL*-norleucine in 80 ml of dioxane in a 500 ml. pressure bottle cooled in an ice bath was added slowly (with swirling) 9 ml of concentrated H_2SO_4 . The resulting mixture was cooled in a dry ice bath as 80 ml of liquid isobutylene was added. The mixture was allowed to warm to room temperature and shaken under autogenous pressure for ~ 23 hours. After most of the isobutylene had been vented off, the slightly hazy solution was cooled in ice and then added to a cold-mixture of 400 ml of 1/*N* NaOH and 500 ml of Et_2O . After shaking in a separate funnel, the layers were separated, and the aqueous fraction was washed with an additional 100 ml of Et_2O . The Et_2O solution was shaken with 150 ml of 0.5 *N* HCl. The acidic aqueous fraction was treated with 2.5 *N* NaOH until strongly basic and then shaken with 250 ml of Et_2O . The Et_2O solution was dried (MgSO_4), filtered, and concentrated on the rotovac. After prolonged pumping on high vacuum over a steam bath, final yield of clear, colorless residual oil = 9.04 g (65%). NMR now showed only a trace of dioxane. TLC (9:1 CHCl_3 —MeOH) showed a single spot.

Step B: *N*-(2,2-Dimethylcyclopropanecarbonyl)-*DL*-norleucine *t*-butyl ester

To a solution of 8.98 g (48 mmole of *DL*-norleucine *t*-butyl ester and 5.05 g (50 mmole) of triethylamine in 100 ml of CH_2Cl_2 , stirred in an ice bath under a drying tube was added dropwise (over a period of 75 min.) a solution of 6.39 g (48 mmole) of 2,2-dimethylcyclopropanecarbonyl chloride (M. Elliot and N.R. James, British Patent No. 1,260,847 (1972)) in 50 ml of CH_2Cl_2 . Precipitation of Et_3N HCl occurred during the addition, especially toward the end. As the ice gradually melted, the mixture was allowed to warm to room temperature. After 16 hrs., the mixture was shaken with 200 ml of 0.5 *N* HCl. The CH_2Cl_2 fraction was washed with an additional 200 ml of 0.5 *N* HCl, then with 2 × 200 ml of 0.5 *N* NaOH, and finally 200 ml of H_2O . The CH_2Cl_2 fraction was dried with MgSO_4 , treated with charcoal, and filtered through Celite. The filtrate was concentrated on the rotovac (finally under high vacuum). Yield of light orange residual oil = 11.93 g (88%). TLC (2:1 hexane-EtOAc) showed a single spot. NMR and IR were in accord with the assigned structure. After standing for several days, the unused portion of this material crystallized: m.p. 52—>65°C.

Step C: *t*-Butyl 2-(2,2-dimethylcyclopropanecarboxamido)-2-methoxyhexanoate

Based on procedure of H. Poisel and V. Schmidt, *Chem. Ber.*, 108 p. 2547 (1975).

To a solution of 6.37 g (22.5 mmole) of *N*-(2,2-dimethylcyclopropanecarbonyl)-*DL*-norleucine *t*-butyl ester in 35 ml of Et_2O stirred at room temperature under N_2 in the dark was added 2.69 ml (2.45 g, 22.5 mmole) of *t*-butyl hypochlorite. After 15 min., a solution of sodium methoxide prepared by dissolving 0.52 g (22.6 mmole) of sodium in 35 ml of MeOH was added. Stirring was continued at ambient temperature under N_2 in the dark. After 16.5 hrs., the precipitated NaCl was filtered off. The filtrate was diluted with Et_2O and washed successively with 3 × 50 ml of 0.5 *N* HCl, 50 ml of saturated Na_2CO_3 , and 2 × 50 ml of H_2O . The Et_2O phase was dried over MgSO_4 and filtered. The filtrate was concentrated on the rotovac. The pale, golden-yellow residual oil (6.45 g) was subjected to preparative high pressure liquid chromatography, resulting in the separation and isolation of 273 mg and 496 mg of the two diastereomers of *t*-butyl 2-(2,2-dimethylcyclopropanecarboxamido)-2-methoxyhexanoate (respective mp's 114—118° and 124—125.5°) as well as 1.97 of a single isomer (apparently Z) of *t*-butyl 2-(2,2-dimethylcyclopropanecarboxamido)-2-hexenoate (colourless oil).

Step D: 2-(2,2-Dimethylcyclopropanecarboxamido)-2-hexenoic acid

A solution of 0.84 g (3.0 mmole) of *t*-butyl 2-(2,2-dimethylcyclopropanecarboxamido)-2-hexenoate in 10 ml of Et_2O saturated with anhydrous HCl was allowed to stand at room temperature under a drying tube. After 17 hrs., the solution was evaporated, and the residual gum was dissolved in 10 ml of saturated NaHCO_3 . This solution was washed with an additional 15 ml of 0.5 *N* HCl, then dried (MgSO_4), filtered, and concentrated to give a viscous oil. The oil was crystallized from toluene. Yield of

0007 614

white crystals = 0.32 g (4.7%), m.p. 119—122°. TLC (4:1 toluene-AcOH) showed a single spot. NMR indicated essentially pure Z-isomer (Note: Treatment of the methanol adduct, t-butyl 2-(2,2-dimethylcyclopropanecarboxamido)-2-methoxyhexenoate, with anhydrous HCl in Et_2O under similar conditions gave the same product.)

5

Example 14

(+)-Z-2-(2,2-Dimethylcyclopropanecarbonylamino)-2-octenoic acid, sodium salt

The reagents, (+)-2,2-dimethylcyclopropanecarboxamide, 7.0 g.; 2-keto-octanoic acid ethyl ester, 14.7 g.; 50 mg. of p-toluenesulfonic acid; and 100 ml. of toluene were charged to a 250 ml. three-necked flask under a Dean Stark trap containing several molecular sieve pellets. The mixture was refluxed vigorously for 27 hours. The resultant light yellow solution was cooled and concentrated *in vacuo*, at a water bath temperature of 45°C., in the presence of water to help remove toluene. The gummy residue was suspended in 230 ml. of 2N NaOH and stirred at 30°C for 3 hours; then the temperature was raised to 35°C for an additional 2-1/2 hrs. until a clear solution formed. The solution was then cooled, 85 ml. methylene chloride added, and the pH adjusted to 8.5 using 4N HCl with stirring. The organic layer was separated and discarded. The aqueous layer (366 ml.) was assayed by liquid chromatography to contain 37.2 mg/ml; 87% Z isomer. Another 85 ml. portion of CH_2Cl_2 was then added and pH adjusted to 4.5 with stirring. The organic layer was separated and the aqueous layer re-extracted with 50 ml. of CH_2Cl_2 , with the pH again adjusted to 4.5. Combined organic extracts were dried over Na_2SO_4 , filtered, and concentrated to a gum. This residue was dissolved in 150 ml. isopropanol and 15 ml. water and the pH adjusted to 8.2 with 2N NaOH. The resulting solution was concentrated to an oily residue which was flushed with isopropanol until it turned to a crystalline solid, indicating that most water had been removed. It was crystallized from 120 ml. of isopropanol, (cooled in ice for 1 hour) filtered, and washed with 50 ml. cold isopropanol followed by copious amounts of acetone. It was dried at 60°C/0.1 mm/2 hours to yield 10.74 g (63.2%) crystalline material, having essentially a single peak in liquid chromatography, m.p. 241—243°C.

The starting material, (+)-2,2-dimethylcyclopropanecarboxamide is most conveniently prepared by resolution of the *D,L* acid, followed by reaction with oxalyl chloride and then ammonia to give the resolved amide.

30 One way of making the starting material is as follows: 23.1 g. of *D,L*-2,2-dimethylcyclopropane-carboxylic acid was suspended in 33 ml H_2O and the pH adjusted to 8.0, using 50% NaOH, about 10 ml. To this was added a solution of 38.4 g. quinine in a mixture of 60 ml. methanol and 30 ml. H_2O to which had been added about 8 ml. of concentrated HCl in another 30 ml. H_2O to give a pH of 7.1. (This was actually a solution of quinine hydrochloride.)

35 These solutions were added all at once, with stirring. The gummy crystalline material which formed was heated to give two clear layers and again stirred vigorously while cooling to give a crystalline product. This product was permitted to stand over two days at room temperature. It was then filtered, washed with 2 x 10 ml. water, and 2 x 10 ml. 50% methanol, and air dried with suction. The yield of crude quinine salt was 44.8 g (48.7% yield) monohydrate, m.p. 113—116°C, having a $[\alpha]_D^{20}$ of —94.3°, C = 1.0; CHCl_3 . This material was recrystallized from acetone to yield 24.35 g, m.p. 127—130°C. This purified quinine salt was converted to the acid by reaction with aqueous base and chloroform, followed by acid, to yield (96%) 3.9 g $[\alpha]_D^{20}$ of +146.0°.

30 This acid was converted to the amide as follows: A charge of 30.5 g (+)acid was added over 5—10 minutes through a dropping funnel to chilled (10°C) oxalyl chloride, 54 ml., containing 1 drop dimethyl-formamide. This was stirred overnight at ambient temperature. A clear solution was observed, which was added to 100 ml. methylene chloride to dilute. Excess oxalyl chloride was removed by concentrating and the mixture flushed twice with methylene chloride.

The resultant solution was diluted with an equal volume of methylene chloride, and added continuously through a dropping funnel to about 100 ml. anhydrous liquid ammonia which was diluted with 100 ml. methylene chloride. A dry ice-acetone cooling bath was used during the addition. When all was added, the cooling bath was removed and the mixture stirred at room temperature for about 1/2 hour. The mixture was filtered, to remove precipitated ammonium chloride, and concentrated to dryness. The crude weight was 26.6 g. (88%). It was redissolved in excess hot ethyl acetate and filtered through a pre-heated sintered glass funnel to separate from trace NH_4Cl . Excess ethyl acetate was atmospherically distilled off. When half the volume remained, 130 ml. of heptane were added, and ethyl acetate was continued to be distilled off, until the boiling point started to rise (to near 80°C; much of product had already crystallized out). Heat was removed, and the mixture let cool gradually to about 30°C, then cooled with an ice bath to 0—5°C for about 1/2 hour. The product was recovered as nice silvery-white crystalline flakes, washed with 3 x ethyl acetate/hexane mixture, 1/1.5 and air dried to constant weight. It weighed 23.3 g (77.1% yield overall, 87.6% recovery from crude), m.p. = 135—138°C (varies with rate of heating). Angle of rotation was determined by dissolving 0.0543 g in 10 ml. chloroform, $[\alpha]_D^{20} = +100.9^\circ$.

65

0 007 614

Example 15

Z-2-(2,2-Dichlorocyclopropanecarboxamido)-2-butenoic acid

Step A: 2,2-Dichlorocyclopropanecarboxamide

A 7.1 g. sample of 2,2-dichlorocyclopropanecarbonyl chloride (U.S. Patent 3,301,896, issued 5 January 31, 1967) was added dropwise to 75 ml of concentrated ammonium hydroxide with vigorous stirring. The temperature of the reaction mixture was maintained below 10°C with an ice bath. The mixture was stirred in the ice bath for 30 min., then at room temperature for 1 hr. The aqueous ammonia was evaporated under reduced pressure (bath at 50°C). The solid residue was extracted with hot ethyl acetate (3 x 30 ml.). The extracts were boiled down to 40 ml. and 20 ml. of hexane was 10 added. After cooling in ice, the solid was filtered, washed with ethyl acetate-hexane (1:1) and dried to give 2.7 g of 2,2-dichlorocyclopropanecarboxamide, m.p. 144—146°. The NMR spectrum was in accord with the desired structure.

	Anal. (C ₁₂ H ₅ Cl ₂ NO)	Calcd.	Found
15		C 31.20	31.26
		H 3.27	3.31
20		N 9.10	9.11
		Cl 46.04	45.79

Another 1.3 g of amide, m.p. 143—145° could be recovered from the mother liquor.

Step B: Z-2-(2,2-Dichlorocyclopropanecarboxamido)-2-butenoic acid


A mixture of 1.53 g (15 mmoles) of 2-ketobutyric acid, 1.54 g (10 mmoles) of 2,2-dichlorocyclopropanecarboxamide and 10 ml of toluene was heated under reflux for 12 hrs. with removal of H₂O by a modified Dean-Stark trap containing molecular sieves (4A). An additional 0.7 g. of 2-ketobutyric acid 30 was added and the reaction mixture was heated under reflux for an additional 12 hrs. The mixture was cooled, diluted with 20 ml. of toluene and extracted with saturated sodium bicarbonate (3 x 10 ml.). The extracts were combined, washed with ether and acidified to pH 3 (pH meter) with concentrated hydrochloric acid. A gum precipitated which soon solidified. It was filtered, washed with water, dried and recrystallized from nitromethane to give 423 mg of Z-2-(2,2-dichlorocyclopropanecarboxamido)-2- 35 butenoic acid, m.p. 188—189.5°C. The NMR spectrum was in accord with the desired structure.

	Anal. (C ₈ H ₉ Cl ₂ NO ₃)	Calcd.	Found
40		C 40.36	40.48
		H 3.81	3.80
		N 5.88	5.91
45		Cl 29.78	29.53

Example 16

Z-2-(2,2-Dichlorocyclopropanecarboxamido)-2-octenoic acid

A mixture of 1.19 g (7.5 mmoles) of 2-keto-octanoic acid, 0.77 g (5.0 mmoles) of 2,2-dichlorocyclopropanecarboxamide, and 5 ml toluene were reacted using the same procedure as in the previous example. The crude product (537 mg) was purified by conversion to the methyl ester (BF₃/CH₃OH), preparative TLC (silica gel G, 4:1 hexane-EtOAc) and saponification of the pure Z-methyl ester (0.3M LiOH/CH₃OH) to give 88 mg of Z-2-(2,2-dichlorocyclopropanecarboxamido)-2-octenoic acid as a partially crystalline gum. NMR Spectrum (DMSO-d₆: 9.68 δ (s, 1H, NH), 6.50 δ (t, 1H, =^H), 55



0007614

Example 17

Z-8-Bromo-2-(2,2-Dimethylcyclopropanecarboxamido)-2-octenoic acid

To a suspension of 14.4 g (0.3 mole) of 50% NaH dispersion in 360 ml of toluene cooled in an ice bath and in a N_2 atmosphere was added over 45 min. a solution of 146 g (0.6 moles) of 1,6-dibromo-
 6 hexane and 57.6 g (0.3 mole) of ethyl 1,3-dithiane-2-carboxylate in 120 ml of DMF. The cooling bath was removed and the mixture stirred at room temperature for 2 hrs. The reaction mixture was washed with water (3 x 210 ml), dried over $MgSO_4$ and evaporated under reduced pressure to give 179.5 g of a yellow oil containing the desired anhydrazine, 1,6-dibromohexane and mineral oil. This crude material was used in the next reaction without purification.
 10 To a suspension of 426 g (2.4 moles) of N-bromosuccinimide in 800 ml of acetonitrile and 200 ml of H_2O was added over 45 min. a solution of the crude dithiane in 100 ml of acetonitrile. The temperature of the reaction mixture was maintained below 25°C with an ice bath. After stirring at 20°C for 10 min. the dark red reaction mixture was poured into 2 l. of hexane- CH_2Cl_2 (1:1). The solution was shaken with saturated $NaHSO_3$ (2 x 400 ml) and water (1 x 500 ml). Then 400 ml of saturated Na_2CO_3 solution was added in small portions (vigorous CO_2 evolution). After the foaming subsided the funnel was shaken and the aqueous phase separated. The organic layer was extracted with saturated Na_2CO_3 solution (400 ml) and water (500 ml) and dried over $MgSO_4$. Removal of the solvent under reduced pressure gave 133.8 g of crude bromo keto-ester containing 1,6-dibromohexane and mineral oil. This crude material was used in the next reaction without purification.
 15 20 A mixture of 133.8 g of crude bromo ketoester, 133 ml of 50% hydrobromic acid and 267 ml of acetic acid was heated at 90°C (internal temperature) for 75 min. The dark solution was evaporated under reduced pressure until most of the acetic acid was removed. The residue was dissolved in 500 ml of ether, washed with water (2 x 100 ml) and extracted with saturated $NaHCO_3$ (3 x 200 ml). The combined $NaHCO_3$ extracts were extracted with ether (2 x 100 ml) and acidified with concentrated HCl.
 25 25 The precipitated oil was extracted with ether (3 x 200 ml). The ether extracts were washed with water (1 x 100 ml) and saturated brine (1 x 100 ml) and dried over $MgSO_4$. Removal of the ether under reduced pressure gave 46.2 g of pure bromoketo acid. Homogeneous by TLC (silica gel, 4:1 toluene-acetic acid). The NMR spectrum was consistent with the desired product.
 30 30 A mixture of 46.1 g (0.194 moles) of the bromoketo acid, 17.6 g (0.156 mole) of 2,2-dimethylcyclopropanecarboxamide and 450 ml of toluene was heated under reflux for 13 hrs., with collection of water in a small Dean-Stark trap. After cooling, the clear reaction mixture was extracted with saturated $NaHCO_3$ solution (4 x 100 ml). The combined extracts were washed with ether (2 x 100 ml) and then the pH was adjusted to 3.5 (pH meter) by addition of concentrated HCl. An oil precipitated which soon crystallized. The solid was filtered, washed well with water and dried. Recrystallization from acetonitrile gave 22.5 g of Z-8-bromo-2-(2,2-dimethylcyclopropanecarboxamido)-2-octenoic acid, m.p. 151—153°C. Homogeneous by TLC (4:1 toluene-acetic acid). The NMR spectrum was consistent with the desired structure.

	Anal. ($C_{14}H_{22}BrNO_3$)	Calcd.	Found
40			
	C	50.61	50.66
	H	6.67	6.96
45			
	N	4.22	4.45
	Br	24.05	23.95

50 The following ω -bromo compounds were prepared using the same procedure:
 Z-6-Bromo-2-(2,2-dimethylcyclopropanecarboxamido)hexenoic acid;
 Z-7-Bromo-2-(2,2-dimethylcyclopropanecarboxamido)heptenoic acid;
 Z-9-Bromo-2-(2,2-dimethylcyclopropanecarboxamido)-2-nonenic acid;
 Z-10-Bromo-2-(2,2-dimethylcyclopropanecarboxamido)decenoic acid;
 Z-8-Bromo-2-(2,2-dimethylcyclopropanecarboxamido)octenoic acid.

55 Example 18
 Z-8-Dimethylamino-2-(2,2-dimethylcyclopropanecarboxamido)-2-octenoic acid

A solution of 664 mg (2 mmoles) of Z-8-bromo-2-(2,2-dimethylcyclopropanecarboxamido)-2-octenoic acid in 10 ml of 40% aqueous dimethylamine was allowed to stand at room temperature for 4 hrs. The solution was poured onto a 3.5 x 20 cm column of Dowex 50W-x8 (100—200 mesh, H^+) ion exchange resin and column eluted with water until the effluent was no longer acidic (~200 ml). The column was then eluted with 300 ml of 2N ammonium hydroxide. The effluent was evaporated under reduced pressure to give 600 mg of a colorless glass. This material was dissolved in 3 ml of ethanol, filtered, and added dropwise to 200 ml of rapidly stirred acetone. A gummy solid precipitated which crystallized upon stirring for two days. The solid was filtered, washed with acetone, and dried to give

0007 614

445 mg of Z-8-dimethylamino-2-(2,2-dimethylcyclopropanecarboxamido)-2-octenoic acid as a colorless, hygroscopic crystals, m.p. 101—112°C. Homogeneous by TLC (silica gel, in BuOH, HOAc, H₂O, 4:1:1). NMR spectrum was consistent with desired structure.

	Anal. (C ₁₆ H ₂₈ N ₂ O ₃ ·H ₂ O)	Calcd.	Found
5		C 61.62	61.03
10		H 9.62	9.28
		N 8.91	8.67

The following 8-amino derivatives were prepared using essentially the same procedure, "DCC" means 2-(2,2-dimethylcyclopropanecarboxamido).

15 Z-10-Dimethylamino-DCC-2-decenoic acid;
 Z-8-Amino-DCC-2-octenoic acid;
 Z-8-Dimethylamino-DCC-2-octenoic acid;
 Z-7-Dimethylamino-DCC-2-heptenoic acid;
 Z-DCC-7-(N-methylpiperazinyl)-2-heptenoic acid;
 20 Z-DCC-8-pyrrolidino-2-octenoic acid;
 Z-DCC-8-(N-methylpiperazinyl)-2-octenoic acid;
 Z-8-Allylamino-DCC-2-octenoic acid;
 Z-DCC-8-piperidino-2-octenoic acid;
 Z-DCC-8-propargylamino-2-octenoic acid;
 25 Z-8-N-[1-Deoxy-(1-methylamino)-D-glucityl]-DCC-2-octenoic acid;
 Z-8-(1-Adamantylamino)-DCC-2-octenoic acid;
 Z-8-Diallylamino-DCC-2-octenoic acid;
 Z-8-DCC-8-(2-hydroxyethylmethylamino)-2-octenoic acid;
 30 Z-8-[(Carboxymethyl)methylamino]-2-(2,2-DCC)-2-octenoic acid;
 Z-2-(2,2-DCC)-8-diethylamino-2-octenoic acid;
 Z-2-(2,2-DCC)-8-[tris-(hydroxymethyl)methylamino]-2-octenoic acid;
 Z-2-(2,2-DCC)-10-(N-methylpiperazinyl)-2-decenoic acid;
 Z-2-(2,2-DCC)-8-[1-(phosphono)ethylamino]-2-octenoic acid;

35 Example 19
 Z-2-(2,2-Dimethylcyclopropanecarboxamido)-8-methylthio-2-octenoic acid
 A stream of CH₃SH gas was bubbled through a solution of 162 mg (3 mmoles) of sodium methoxide in 5 ml of methane for 10 min. with cooling in an ice bath. The solution was allowed to warm to room temperature and 332 mg (1 mmole) of Z-8-bromo-2-(2,2-dimethylcyclopropanecarboxamido)-2-octenoic acid was added. The solution was heated under reflux for 30 min. in a N₂ atmosphere. Most of the methanol was evaporated under reduced pressure, the residue was dissolved in 10 ml of water and acidified with 2.5 N HCl. The precipitated oil was extracted with ether (3 x). The ether extracts were washed with water, saturated in brine and dried over MgSO₄. Removal of the ether under reduced pressure gave a colorless oil that crystallized upon standing. It was recrystallized from ether-hexane to give 178 mg of Z-2-(2,2-dimethylcyclopropanecarboxamido)-8-methylthio-2-octenoic acid, m.p. 82—84°C. Homogeneous by TLC (toluene-acetic acid, 4:1). The NMR spectrum was in accord with the desired structure.

	Anal. (C ₁₅ H ₂₅ NO ₃ S)	Calcd.	Found
50		C 60.18	60.36
		H 8.42	8.68
55		N 4.68	4.59
		S 10.69	10.87

60 The following compounds were prepared by similar methods, "DCC" means 2-(2,2-dimethylcyclopropanecarboxamido).

Z-DCC-8-ethoxythiocarbonylthio-2-octenoic acid;
 Z-DCC-8-(1-methyl-5-tetrazolylthio)-2-octenoic acid;
 Z-DCC-7-[(methoxycarbonyl)methylthio]-2-heptenoic acid;
 Z-8-Acetylthio-DCC-2-octenoic acid;
 65 Z-7-[(2-Amino-2-oxoethyl)thio]-DCC-2-heptenoic acid;

0007614

6-(L-2-Amino-2-carboxyethylthio)-2-(2,2-DCC-2-hexenoic acid;
 Z-8-(Carbomethoxymethylthio)-2-(2,2-DCC)-2-octenoic acid;
 Z-6-(Carbomethoxymethylthio)-2-(2,2-DCC)-2-hexenoic acid;
 Z-2-(2,2-DCC)-6-(phosphonomethylthio)-2-hexenoic acid.

5

Example 20

Z-2-(2,2-Dimethylcyclopropanecarboxamido)-8-trimethylammonium hydroxide-2-octenoic acid inner salt

10 A solution of 996 mg (3 mmoles) of Z-8-bromo-2-(2,2-dimethylcyclopropanecarboxamido)-2-octenoic acid in 15 ml of 25% aqueous trimethylamine was allowed to stand at room temperature for 3 hrs. The reaction mixture was poured onto a 2 x 25 cm column of IRA-410 (50—100 mesh, OH⁻) ion exchange resin and eluted with water until the effluent was no longer basic. The effluent was evaporated under reduced pressure to give 800 mg of a colorless glass. This material was dissolved in 20 ml. of ethanol, filtered and diluted with 600 ml of acetone. After standing at room temperature overnight 15 the crystalline solid which deposited was filtered, washed with acetone and dried to give 720 mg of Z-2-(2,2-dimethylcyclopropanecarboxamido)-8-trimethylammonium hydroxide-2-octenoic acid inner salt as hygroscopic crystals, m.p. 220—222°C. Homogeneous by TLC (silica gel, in BuOH, HOAc, H₂O, 4:1:1). NMR spectrum was consistent with desired structure.

20

	Anal. (C ₁₇ H ₃₀ N ₂ O ₃)	Calcd.	Found
	C	65.77	65.78
25	H	9.74	9.98
	N	9.02	8.92

Other quaternary derivatives were prepared using essentially the same procedure; these are Z-2-(2,2-Dimethylcyclopropanecarboxamido)-8-trimethylammonium hydroxide-2-octenoic acid 30 inner salt; Z-2-(2,2-Dimethylcyclopropanecarboxamido)-8-pyridinium hydroxide-2-octenoic acid inner salt; Z-2-(2,2-Dimethylcyclopropanecarboxamido)-8-(2-hydroxyethyldimethylammonium hydroxide)-2-octenoic acid inner salt; Z-2-(2,2-Dimethylcyclopropanecarboxamido)-10-trimethylammonium hydroxide-2-decenoic acid 35 inner salt; Z - 8 - (Benzylidimethylammonium hydroxide) - 2 - (2,2 - dimethylcyclopropanecarboxamido) - 2-octenoic acid inner salt; Z - 10 - (Benzylidimethylammonium hydroxide) - 2 - (2,2 - dimethylcyclopropanecarboxamido) - 2-decenoic acid inner salt; 40 Z - 2 - (2,2 - Dimethylcyclopropanecarboxamido) - 9 - trimethylammonium hydroxide - 2 - nonenoic acid inner salt; Z - 8 - (2 - Dimethylaminoethylidimethylammonium hydroxide) - 2 - (2,2 - dimethylcyclopropane-carboxamido) - 2 - octenoic acid inner salt; Z-2-(2,2-Dichlorocyclopropanecarboxamido)-8-trimethylammonium hydroxide-2-octenoic acid 45 inner salt;

Example 21

Z-2-(2,2-Dimethylcyclopropanecarboxamido)-8-formamidino-2-octenoic acid

50 A 350 mg sample of Z-8-amino-2-(2,2-dimethylcyclopropanecarboxamido)-2-octenoic acid was dissolved in 10 ml of water and the pH adjusted to 8.5 with 2.5N NaOH. A total of 947 mg of benzyl formimidate hydrochloride was added at room temperature in small portions over 20 min. while the pH was maintained between 8—9 by addition of 2.5N NaOH. After stirring at room temperature for 30 min., the cloudy reaction mixture was extracted with ether (3 x) and applied to a 2 x 2.5 cm column of a G50W-X4 (Na⁺, 200—400 mesh) resin. After elution with water, the fractions containing the product 55 were pooled and evaporated under reduced pressure. This material was dissolved in water and applied to a 2 x 25 cm column of a G1X8 (HCO₃⁻, 200—400 mesh) resin. After elution with water, the fractions containing pure product were pooled and evaporated under reduced pressure. The residue was dissolved in a few ml of warm ethanol, filtered, and added dropwise to 200 ml of ether with rapid stirring. Filtration and washing with ether gave 243 mg of Z-2-(2,2-dimethylcyclopropanecarbox-60 amido)-8-formamidino-2-octenoic acid as an amorphous solid. Homogeneous by TLC (n-BuOH, HOAc, H₂O; 4:1:1). The NMR spectrum was in accord with the desired structure.

0007 614

	Anal. (C ₁₅ H ₂₅ N ₃ O ₃ ·1/3H ₂ O)	Calcd.	Found
		C 59.96	60.04
		H 8.59	8.64
5		N 13.92	13.57

10 The following amidino compounds were prepared using the similar procedures:
 Z-8-Acetamidino-2-(2,2-dimethylcyclopropanecarboxamido)-2-octenoic acid;
 Z-8-Benzylamidino-2-(2,2-dimethylcyclopropanecarboxamido)-2-octenoic acid;
 Z-2-(2,2-Dimethylcyclopropanecarboxamido)-10-formamidino-2-decanoic acid;
 Z-2-(2,2-Dimethylcyclopropanecarboxamido)-8-(2-imidazoyl-2-yl-amino)-2-octenoic acid.

Example 22

15 Z-2-(2,2-Dimethylcyclopropanecarboxamido)-8-guanidino-2-octenoic acid

To a solution of 2 mmoles of guanidine (prepared from 432 mg of guanidine sulfate and 630 mg of barium hydroxide octahydrate) in 7 ml of water was added 332 mg (1 mmole) of 8-bromo-2-(2,2-dimethylcyclopropanecarboxamido)octenoic acid, and the solution was heated at 70°C in a nitrogen atmosphere for 1 hr. The reaction mixture was applied to a 2 x 25 cm column of Dowex 50W-X8 (H⁺, 20 100—200 mesh). After elution with water the fractions containing the product were pooled and evaporated under reduced pressure. The residue was dissolved in several ml of warm ethanol and added dropwise to 100 ml of ether with rapid stirring. Filtration and washing with ether gave 107 mg of Z-2-(2,2-dimethylcyclopropanecarboxamido)-8-guanidino-2-octenoic acid as an amorphous electrostatic powder. Homogeneous by TLC (n-BuOH, HOAc, H₂O; 4:1:1). NMR (D₂O, NaOD): 6.48 δ (t, 1H, =¹H); 25 3.10 δ (m, 2H, CHN—), 2.10 δ (m, 2H, =¹CH₂), 1.17 δ



The following guanidino compound was prepared using the same procedure:

35 Z-2-(2,2-dimethylcyclopropanecarboxamido)-8-(N,N-dimethylguanidino)-2-octenoic acid.

Example 23

Z-2-(2,2-Dimethylcyclopropanecarboxamido)-8-methyl-2-octenoic acid

To a solution of 2.43 mmoles of sodium methoxide in 5 ml of methanol was added 332 mg (1 mmole) of 8-bromo-2-(2,2-dimethylcyclopropanecarboxamido)-2-octenoic acid. The solution was heated under reflux in a nitrogen atmosphere for 1 hr. The reaction mixture was evaporated under reduced pressure, the residue dissolved in water and acidified with 2.5 N hydrochloric acid. The oil which precipitated was extracted with ether (3 x). The ether extracts were washed with water, and saturated brine and dried over MgSO₄. Removal of the ether under reduced pressure gave a colorless oil that 40 crystallized upon standing. It was recrystallized from ether-hexane to give 140 mg of Z-2-(2,2-dimethylcyclopropanecarboxamido)-8-methoxy-2-octenoic acid, m.p. 71—72°C. Homogeneous by TLC (toluene-HOAc, 4:1). The NMR spectrum was in accord with the desired structure.

	Anal. (C ₁₅ H ₂₅ NO ₄)	Calcd.	Found
50		C 63.58	63.54
		H 8.89	9.12
55		N 4.94	5.16

Using similar procedures, the following compounds were prepared:

60 Z-8-Cyano-2-(2,2-dimethylcyclopropanecarboxamido)-2-octenoic acid;
 Z-7-Cyano-2-(2,2-dimethylcyclopropanecarboxamido)-2-heptenoic acid;
 Z-9-Cyano-2-(2,2-dimethylcyclopropanecarboxamido)nonenoic acid;
 Z-2-(2,2-Dimethylcyclopropanecarboxamido)-7-sulfo-2-heptenoic acid sodium salt;
 Z-2-(2,2-Dimethylcyclopropanecarboxamido)-8-sulfo-2-octenoic acid sodium salt;
 Z-2-(2,2-Dimethylcyclopropanecarboxamido)-8-hydroxy-2-octenoic acid;
 Z-8-Acetoxy-2-(2,2-dimethylcyclopropanecarboxamido)-2-octenoic acid.

65


0 007 614

Claims for the Contracting States: BE CH DE FR GB IT LU NL SE


5 1. Antibacterial composition characterized in that it contains a combination of a thienamycin type compound with is a 6-substituted and optionally 2-substituted pen-2-em-3-carboxylic acid, a 1-carbadethia-pen-2-em-3-carboxylic acid or 1-azabicyclo[3.2.0]hept-2-ene-7-one-2-carboxylic acid and a dipeptidase (E.C.3.4.13.11) inhibitor, the weight ratio of the first named material to the dipeptidase inhibitor being within the range of 1:3 to 30:1.

10 2. The composition of Claim 1 in which the first named material is a compound of the following formula

15



20 25 wherein X can be CH₂ or S; R² can be hydrogen; —S—CH₂CH₂NHR³, wherein R³ is hydrogen, acetyl, formimidoyl, acetimidoyl; —S(O)—CH=CHNHCOCH₃ and —S—CH=CHNHCOCH₃; and R⁶ is



25 30 wherein R⁷ is hydrogen, hydroxy or hydroxy-sulfonyloxy, or R⁸ is H, including all possible stereoisomeric forms.

3. The composition of Claim 1 or 2 in which the combination is mixed with a pharmaceutical carrier.

30 4. The composition of Claim 3 in which the carrier is adapted for injection.


5. The composition of Claims 1 or 2 in which the thienamycin-type compound is thienamycin.

6. The composition of Claim 1 or 2 in which the thienamycin-type compound is N-formimidoylthienamycin.

7. The composition of Claim 1 or 2 in which the thienamycin-type compound is N-acetimidoylthienamycin.

35 8. The composition of Claim 1 or 2 in which the dipeptidase inhibitor is a compound of the following formula:

40



45 50 wherein R⁹ and R¹⁰ are hydrocarbon radicals in the range respectively of 3—10 and 1—15 carbon atoms; in either one of these R⁹ or R¹⁰ hydrocarbon chains 1—6 hydrogens may be replaced by halogens or a non-terminal methylene may be replaced by oxygen or sulfur, including oxidized forms of the latter; additionally, a terminal hydrogen in R¹⁰ can also be replaced by a hydroxyl or thiol group, which may be acylated or carbamoylated; or the hydrogen can be replaced by an amino group, which may be derivatized as in an acylamino, ureido, amidino, guanidino, or alkyl or substituted amino group, including quaternary nitrogen groupings; or, alternatively, there may be replacement by acid groups such as carboxylic, phosphonic or sulfonic acid groups or esters or amides thereof, as well as cyano; or combinations thereof, such as terminal amino acid grouping; and R¹ is hydrogen or lower alkyl (C_{1—6}) or dialkylaminoalkyl, or a pharmaceutically acceptable cation.

55 55 9. The composition of claim 8 in which R⁹ is a straight, branched or cycloalkyl group of 3—10 carbon atoms including alkylcycloalkyl and dialkylcycloalkyl, providing the carbon adjacent to the carbonyl cannot be tertiary.

60 60 10. The composition of Claim 8 in which R⁹ can be R⁴, wherein R⁴ is branched or cyclic hydrocarbon of 3—10 carbon atoms;

—R⁵R¹¹, wherein R⁵ is cycloalkyl of 3—6 carbon atoms and R¹¹ is either 1 or 2 alkyl substituents which may be joined to form another ring on the cycloalkyl group or R¹¹ is 1 or 2 chloro substituents;

65 65 —R¹²R⁸, wherein R¹² is alkylene of 1—3 carbon atoms and R⁸ is cycloalkyl of 3—6 carbon atoms.

11. The composition of Claim 8 in which R⁹ is 2,2-dimethylcyclopropyl.

0 007 614

12. The composition of Claim 8 in which R⁹ is 2,2-dichlorocyclopropyl.


13. The composition of Claim 8 in which the dipeptidase inhibitor is Z-2-(2,2-dimethylcyclopropanecarboxamido)-2-octenoic acid.

5 Claims for the Contracting State: AT

1. Process for preparing an antibacterial composition characterized in mixing a thienamycin type compound which is a 6-substituted and optionally a 2-substituted pen-2-em-3-carboxylic acid, a 1-carbadethia-pen-2-em-3-carboxylic acid or 1-azabicyclo[3.2.0]hept-2-ene-7-one-2-carboxylic acid and 10 a dipeptidase (E.C.3.4.13.11) inhibitor, the weight ratio of the first named material to the dipeptidase inhibitor being within the range of 1:3 to 30:1.

2. Process according to claim 1 in which the first named material is a compound of the following formula


15



20

wherein X can be CH₂ or S; R² can be hydrogen; —S—CH₂CH₂NHR³, wherein R³ is hydrogen, acetyl, formimidoyl, acetimidoyl; —S(O)—CH=CHNHCOCH₃ and —S—CH=CHNHCOCH₃; and R⁶ is

25



wherein R⁷ is hydrogen, hydroxy or hydroxy-sulfonyloxy, or R⁶ is H, including all possible stereoisomeric forms.

30

3. Process according to Claim 1 or 2 in which the components are mixed with a pharmaceutical carrier.

4. Process according to Claim 3 in which the carrier is adapted for injection.

5. Process according to Claim 1 or 2 in which the thienamycin-type compound is thienamycin.

6. Process according to Claim 1 or 2 in which the thienamycin-type compound is N-formimidoyl-


35

thienamycin.

7. Process according to Claims 1 or 2 in which the thienamycin-type compound is N-acetimidoyl-thienamycin.

8. Process according to Claim 1 or 2 in which the dipeptidase inhibitor is a compound of the following formula:

40



45

wherein R⁹ and R¹⁰ are hydrocarbon radicals in the range respectively of 3—10 and 1—15 carbon atoms; in either one of these R⁹ or R¹⁰ hydrocarbon chains 1—6 hydrogens may be replaced by halogens or a non-terminal methylene may be replaced by oxygen or sulfur, including oxidized forms of the latter; additionally, a terminal hydrogen in R¹⁰ can also be replaced by a hydroxyl or thiol group, which may be acylated or carbamoylated; or the hydrogen can be replaced by an amino group, which may be derivatized as in an acylamino, ureido, amidino, guanidino, or alkyl or substituted alkylamino group, including quaternary nitrogen groupings; or, alternatively, there may be replacement by acid groups such as carboxylic, phosphonic or sulfonic acid groups or esters or amides thereof, as well as cyano; or combinations thereof, such as a terminal amino acid grouping; and R¹ is hydrogen or lower alkyl (C₁₋₆) or dialkylaminoalkyl, or a pharmaceutically acceptable cation.

50

9. Process according to Claim 8 in which R⁹ is a straight, branched or cycloalkyl group of 3—10 carbon atoms including alkylcycloalkyl and dialkylcycloalkyl, providing the carbon adjacent to the carbonyl cannot be tertiary.

10. Process according to Claim 8 in which R⁹ in the dipeptidase inhibitor can be R⁴, wherein R⁴ is branched or cyclic hydrocarbon of 3—10 carbon atoms;

55

—R⁵R¹¹, wherein R⁵ is cycloalkyl of 3—6 carbon atoms and R¹¹ is either 1 or 2 alkyl substituents which may be joined to form another ring on the cycloalkyl group or R¹¹ is 1 or 2 chloro substituents;

0 007 614

—R¹²R⁸, wherein R¹² is alkylene of 1—3 carbon atoms and R⁸ is cycloalkyl of 3—6 carbon atoms.

11. Process according to Claim 8 in which R⁹ in the dipeptidase inhibitor is 2,2-dimethylcyclopropyl.

12. Process according to Claim 8 in which R⁹ in the dipeptidase inhibitor is 2,2-dichlorocyclopropyl.

13. Process according to Claim 8 in which the dipeptidase inhibitor is Z-2-(2,2-dimethylcyclopropanecarboxamido)-2-octenoic acid.


Revendications pour les Etats contractants: BE CH DE FR GB IT LU NL SE

10

1. Composition antibactérienne caractérisée en ce qu'elle contient une combinaison d'un composé du type thiénamycine qui est un acide pen-2-em-3-carboxylique 6-substitué et éventuellement 2-substitué, un acide 1-carbadéthia-pen-2-em-3-carboxylique ou 1-azabicyclo[3.2.0]-hept-2-ène-7-one-2-carboxylique et un inhibiteur de dipeptidase (E.C.3.4.13.11), le rapport pondéral de la matière nommée en premier à l'inhibiteur de dipeptidase étant dans un intervalle de 1:3 à 30:1.

15. 2. Composition selon la revendication 1 où la matière nommée en premier est un composé de formule


20



25

où X peut être CH, ou S; R² peut être unhydrogène; —S—CH₂CH₂NHR³, où R³ est un hydrogène, un acétyle, un formimidoyle, un acétimidoyle; —S(O)—CH=CHNHCOCH₃ et —S—CH=CHNHCOCH₃; et R⁶ est

30



où R⁷ est un hydrogène, un hydroxy ou un hydroxy-sulfonyloxy, ou R⁶ est H, y compris toutes les formes stéréoisomériques possibles.

35. 3. Composition selon l'une des revendications 1 ou 2 où la combinaison est mélangée à un support pharmaceutique.

4. Composition selon la revendication 3 où le support est adapté à l'injection.


5. Composition selon l'une des revendications 1 ou 2 où le composé du type thiénamycine est la 40 thiénamycine.

6. Composition selon l'une des revendications 1 ou 2 où le composé du type thiénamycine est la N-formimidoylthiénamycine.

7. Composition selon l'une des revendications 1 ou 2 où le composé du type thiénamycine est la N-acétimidoylthiénamycine.

45. 8. Composition selon l'une des revendications 1 ou 2 où l'inhibiteur de dipeptidase est un composé de formule

50



55

où R⁹ et R¹⁰ sont des radicaux hydrocarbonés dans un intervalle, respectivement, de 3—10 et 1—15 atomes de carbone; dans l'une ou l'autre de ces chaînes hydrocarbonées R⁹ ou R¹⁰, de 1 à 6 atomes d'hydrogène peuvent être remplacés par des halogènes, ou un méthylène non-terminal peut être remplacé par un oxygène ou un soufre, y compris les formes oxydées de ce dernier; en outre, un hydrogène terminal dans R¹⁰ peut également être remplacé par un groupe hydroxyle ou thiol, qui peut être acylé ou carbamoylé; ou l'hydrogène peut être remplacé par un groupe amino, qui peut être sous forme de groupe dérivé, comme dans acylamino, uréido, amidino, ou un groupe alcoyle ou alcoylamino substitué, y compris les groupements azote quaternaire; ou encore il peut y avoir remplacement par des groupes acides comme des groupes acide carboxylique, phosphonique ou sulfonique ou leurs esters ou amides, ainsi que cyano; ou leurs combinaisons, comme un groupement acide aminé terminal; et R¹ est

0 007 614

un hydrogène ou un alcoyle inférieur (en C₁ à C₆) ou dialcoylaminoalcoyle, ou un cation pharmaceutiquement acceptable.

9. Composition selon la revendication 8 où R⁹ est un groupe à chaîne droite, ramifiée ou cycloalcoyle en C₃ à C₁₀, y compris alcoylcycloalcoyle et dialcoylcycloalcoyle, avec la précision que l'atome de carbone adjacent au carbonyle ne peut être tertiaire.

10. Composition selon la revendication 8 où R⁹ peut être R⁴, où R⁴ est un hydrocarbure à chaîne ramifiée ou cyclique en C₃ à C₁₀:

—R⁵R¹¹, où R⁵ est un cycloalcoyle en C₃ à C₆ et R¹¹ représente 1 ou 2 substituants alcoyle qui peuvent être réunis pour former un autre noyau sur le groupe cycloalcoyle ou R¹¹ représente 1 ou 2 substituants chloro;

—R¹²R⁸, où R¹² est un alcoylène en C₁ à C₃ et R⁸ est un cyclo-alcoyle en C₃ à C₆.

11. Composition selon la revendication 8 où R⁹ est un 2,2-diméthylcyclopropyle.

12. Composition selon la revendication 8 où R⁹ est un 2,2-dichlorocyclopropyle.


13. Composition selon la revendication 8 où l'inhibiteur de dipeptidase est l'acide Z-2-(2,2-diméthylcyclopropanecarboxamido)-2-octénoïque.

Revendications pour l'Etat contractant: AT


1. Procédé de préparation d'une composition antibactérienne caractérisé en ce qu'on mélange un composé du type thiénamycine qui est un acide pen-2-em-3-carboxylique 6-substitué et éventuellement 2-substitué, un acide 1-carbadéthia-pen-2-em-3-carboxylique ou 1-azabicyclo[3.2.0]-hept-2-ène-7-one-2-carboxylique et un inhibiteur de dipeptidase (E.C.3.4.13.11), le rapport pondéral de la matière nommée en premier à l'inhibiteur de dipeptidase étant dans un intervalle de 1:3 à 30:1.

2. Procédé selon la revendication 1 où la matière nommée en premier est un composé de formule

25



35 où X peut être CH₂ ou S; R² peut être un hydrogène; —S—CH₂CH₂NHR³, où R³ est un hydrogène, un acétyle, un formimidoyle, un acétimidoyle; —S(O)—CH=CHNHCOCH₃ et —S—CH=CHNHCOCH₃; et R⁶ est



40 où R⁷ est un hydrogène, un hydroxy ou un hydroxy-sulfonyloxy, ou R⁶ est H, y compris toutes les formes stéréoisomériques possibles.

3. Procédé selon l'une des revendications 1 ou 2 où l'on mélange les composants avec un support pharmaceutique.

4. Procédé selon la revendication 3 où le support est adapté à l'injection.

5. Procédé selon l'une des revendications 1 ou 2 où le composé du type thiénamycine est la thiénamycine.

6. Procédé selon l'une des revendications 1 ou 2 où le composé du type thiénamycine est la N-formimidoylthiénamycine.

7. Procédé selon l'une des revendications 1 ou 2 où le composé du type thiénamycine est la N-acétimidoylthiénamycine.

8. Procédé selon l'une des revendications 1 ou 2 où l'inhibiteur de dipeptidase est un composé de formule

55



où R⁹ et R¹⁰ sont des radicaux hydrocarbonés dans un intervalle, respectivement, de 3—10 et 1—15 atomes de carbone; dans l'une ou l'autre de ces chaînes hydrocarbonées R⁹ ou R¹⁰, de 1 à 6 atomes d'hydrogène peuvent être remplacés par des halogènes, ou un méthylène non-terminal peut être remplacé par un oxygène ou un soufre, y compris les formes oxydées de ce dernier; en outre, un hydrogène

65

0 007 614

terminal dans R¹⁰ peut également être remplacé par un groupe hydroxyle ou thiol, qui peut être acylé ou carbamoylé; ou l'hydrogène peut être remplacé par un groupe amino, qui peut être sous forme de groupe dérivé, comme dans acylamino, uréido, amidino, guanidino, ou un groupe alcoyle ou alcoylamino substitué, y compris les groupements azote quaternaire; ou encore il peut y avoir remplacement par des groupes acides comme des groupes acide carboxylique, phosphonique ou sulfonique ou leurs esters ou un hydrogène ou un alcoyle inférieur (en C₁ à C₆) ou dialcoylaminoalcoyle, ou un cation pharmaceutiquement acceptable.

9. Procédé selon la revendication 8 où R⁹ est un groupe à chaîne droite, ramifiée ou cycloalcoyle en C₃ à C₁₀, y compris alcoylcycloalcoyle et dialcoylcycloalcoyle, avec la précision que l'atome de carbone adjacent au carbonyle ne peut être tertiaire.

10. Procédé selon la revendication 8 où R⁹ dans l'inhibiteur de dipeptidase peut être R⁴, où R⁴ est un hydrocarbure à chaîne ramifiée ou cyclique en C₃ à C₁₀;

11. Procédé selon la revendication 8 où R⁹ dans l'inhibiteur de dipeptidase est R¹¹, où R¹¹ représente 1 ou 2 substituants alcoyle qui peuvent être réunis pour former un autre noyau sur le groupe cycloalcoyle ou R¹¹ représente 1 ou 2 substituants chloro;

—R¹²R⁸, où R¹² est un alcoylène en C₁ à C₃ et R⁸ est un cyclo-alcoyle en C₃ à C₆.

12. Procédé selon la revendication 8 où R⁹ dans l'inhibiteur de dipeptidase est le 2,2-diméthylcyclopropyle.

13. Procédé selon la revendication 8 où l'inhibiteur de dipeptidase est l'acide Z-2-(2,2-diméthylcyclopropanecarboxamido)-2-octénoïque.

25 Patentansprüche für die Vertragsstaaten: BE CH DE FR GB IT LU NL SE


1. Antibakterielle Zusammensetzung, dadurch gekennzeichnet, daß sie eine Kombination aus einer Verbindung vom Thienamycin-Typ, welche Verbindung eine 6-substituierte und gegebenenfalls 2-substituierte Pen-2-em-3-carbonsäure, eine 1-Carbadethia-pen-2-em-3-carbonsäure oder eine 1-Azabicyclo[3.2.0]hept-2-en-7-on-2-carbonsäure ist, und einem Dipeptidase (E.C.3.4.13.11)-Inhibitor enthält, wobei das Gewichtsverhältnis des erstgenannten Materials zu dem Dipeptidaseinhibitor im Bereich von 1:3 bis 30:1 liegt.

2. Die Zusammensetzung nach Anspruch 1, in der das erstgenannte Material eine Verbindung der nachstehenden Formel



ist, worin X CH₂, S sein kann; R² Wasserstoff; —S—CH₂CH₂NHR³, worin R³ Wasserstoff, Acetyl, Formimidoyl, Acetimidoyl ist; —S(O)—CH=CHNHCOCH₃ und —S—CH=CHNHCOCH₃ sein kann; und R⁶

45



50 ist, worin R⁷ Wasserstoff, Hydroxy oder Hydroxysulfonyloxy ist, oder R⁸ Wasserstoff ist, einschließlich aller möglichen stereoisomeren Formen.

3. Die Zusammensetzung nach Anspruch 1 oder 2, in der die Kombination mit einem pharmazeutischen Träger vermischt ist.

4. Die Zusammensetzung nach Anspruch 3, in der der Träger zur Injektion angepaßt ist.

5. Die Zusammensetzung nach Anspruch 1 oder 2, in der die Thienamycin-Typ-Verbindung Thienamycin ist.

6. Die Zusammensetzung nach Anspruch 1 oder 2, in der die Thienamycin-Typ-Verbindung N-Formimidoylthienamycin ist.


7. Die Zusammensetzung nach Anspruch 1 oder 2, in der die Thienamycin-Typ-Verbindung N-Acetimidoylthienamycin ist.

8. Die Zusammensetzung nach Anspruch 1 oder 2, in der der Dipeptidaseinhibitor eine Verbindung der folgenden Formel ist.

65

0007 614

5



worin R^9 und R^{10} Kohlenwasserstoffreste im Bereich von 3—10 bzw. 1—15 Kohlenstoffatomen sind; wobei in jeder dieser R^9 - oder R^{10} -Kohlenwasserstoffketten 1—6 Wasserstoffe ersetzt sein können durch Halogene oder ein nicht endständiges Methylen ersetzt sein kann durch Sauerstoff oder Schwefel, einschließlich der oxydierten Formen des letzteren; ferner ein endständiger Wasserstoff in R^{10} auch ersetzt sein kann durch eine Hydroxyl- oder Thiolgruppe, die acyliert oder carbamoyliert sein kann; oder der Wasserstoff ersetzt sein kann durch eine Aminogruppe, die in Derivatform vorliegen kann; oder der Wasserstoff ersetzt sein kann durch eine Carbonylgruppe, die in Derivatform vorliegen kann, wie in einer Acylamino-, Ureido-, Amidino-, Guanidino- oder Alkyl- oder substituierten Alkylamino-gruppe, einschließlich quaternärer Stickstoffgruppen; oder alternativ ein Ersatz durch saure Gruppen vorliegen kann, wie Carbonsäure-, Phosphonsäure- oder Sulfonsäuregruppen oder Ester oder Amide davon, sowie Cyano; oder Kombinationen davon, wie eine endständige Aminosäuregruppe; und R^1 Wasserstoff oder Niedrigalkyl(C_{1-6}) oder Dialkylaminoalkyl oder ein pharmazeutisch brauchbares Kation ist.

9. Die Zusammensetzung nach Anspruch 8, in der R^9 eine gerade, verzweigte oder Cyclo-alkylgruppe mit 3 bis 10 Kohlenstoffatomen einschließlich Alkylcycloalkyl und Dialkylcycloalkyl ist, vorausgesetzt, daß der zur Carbonylgruppe benachbarte Kohlenstoff nicht tertiär sein kann.

10. Die Zusammensetzung nach Anspruch 8, in der R^9 sein kann R^4 , worin R^4 verzweigter oder cyclischer Kohlenwasserstoff mit 3—10 Kohlenstoffatomen ist;

— R^5R^{11} , worin R^5 Cycloalkyl mit 3—6 Kohlenstoffatomen ist und R^{11} entweder 1 oder 2 Alkylsubstituenten ist, die verbunden sein können unter Bildung eines weiteren Ringes an der Cycloalkylgruppe oder R^{11} 1 oder 2 Chlorsubstituenten bedeutet;

— $R^{12}R^8$, worin R^{12} Alkylen mit 1 bis 3 Kohlenstoffatomen ist und R^8 Cycloalkyl mit 3 bis 6 Kohlenstoffatomen ist.

11. Die Zusammensetzung nach Anspruch 8, in der R^9 2,2-Dimethylcyclopropyl ist.

12. Die Zusammensetzung nach Anspruch 8, in der R^9 2,2-Dichlorcyclopropyl ist.


13. Die Zusammensetzung nach Anspruch 8, in der der Dipeptidaseinhibitor Z-2-(2,2-Dimethylcyclopropancarboxamido)-2-octensäure ist.

35 Patentansprüche für den Vertragsstaat: AT

1. Verfahren zur Herstellung einer antibakteriellen Zusammensetzung, gekennzeichnet durch Verbindungen einer Verbindung vom Thienamycin-Typ, welche Verbindung eine 6-substituierte und gegebenenfalls 2-substituierte Pen-2-em-3-carbonsäure, eine 1-Carbadethia-pen-2-em-3-carbonsäure oder eine 1-Azabicyclo[3.2.0]hept-2-en-7-on-2-carbonsäure ist, und eines Dipeptidase (E.C.3.4.13.11)-Inhibitors, wobei das Gewichtsverhältnis des erstgenannten Materials zu dem Dipeptidaseinhibitor im Bereich von 1:3 bis 30:1 liegt.


2. Verfahren nach Anspruch 1, in dem das erstgenannte Material eine Verbindung der nachstehenden Formel:

50



ist, worin X CH_2 oder S sein kann; R^2 Wasserstoff; — $S—CH_2CH_2NHR^3$, worin R^3 Wasserstoff, Acetyl, Formimidoyl, Acetimidoyl ist; — $S(O)CH=CHNHCOCH_3$ und — $S—CH=CHNHCOCH_3$ sein kann; und R^6

60




ist, worin R^7 Wasserstoff, Hydroxy oder Hydroxysulfonyloxy ist, oder R^6 Wasserstoff ist, einschließlich aller möglichen stereoisomeren Formen.

3. Verfahren nach Anspruch 1 oder 2, in dem die Bestandteile mit einem pharmazeutischen Träger vermischt werden.

0007614

4. Verfahren nach Anspruch 3, in dem der Träger zur Injektion angepaßt ist.
5. Verfahren nach Anspruch 1 oder 2, in dem die Thienamycin-Typ-Verbindung Thienamycin ist.
6. Verfahren nach Anspruch 1 oder 2, in dem die Thienamycin-Typ-Verbindung N-Formimidoylthienamycin ist.
- 5 7. Verfahren nach Anspruch 1 oder 2, in dem die Thienamycin-Typ-Verbindung N-Acetimidoylthienamycin ist.
8. Verfahren nach Anspruch 1 oder 2, in dem der Dipeptidaseinhibitor eine Verbindung der folgenden Formel ist.

10



15 20 25 30 35 40 45 50 55 60 65 70 75 80 85 90 95 100 105 110 115 120 125 130 135 140 145 150 155 160 165 170 175 180 185 190 195 200 205 210 215 220 225 230 235 240 245 250 255 260 265 270 275 280 285 290 295 300 305 310 315 320 325 330 335 340 345 350 355 360 365 370 375 380 385 390 395 400 405 410 415 420 425 430 435 440 445 450 455 460 465 470 475 480 485 490 495 500 505 510 515 520 525 530 535 540 545 550 555 560 565 570 575 580 585 590 595 600 605 610 615 620 625 630 635 640 645 650 655 660 665 670 675 680 685 690 695 700 705 710 715 720 725 730 735 740 745 750 755 760 765 770 775 780 785 790 795 800 805 810 815 820 825 830 835 840 845 850 855 860 865 870 875 880 885 890 895 900 905 910 915 920 925 930 935 940 945 950 955 960 965 970 975 980 985 990 995 1000 1005 1010 1015 1020 1025 1030 1035 1040 1045 1050 1055 1060 1065 1070 1075 1080 1085 1090 1095 1100 1105 1110 1115 1120 1125 1130 1135 1140 1145 1150 1155 1160 1165 1170 1175 1180 1185 1190 1195 1200 1205 1210 1215 1220 1225 1230 1235 1240 1245 1250 1255 1260 1265 1270 1275 1280 1285 1290 1295 1300 1305 1310 1315 1320 1325 1330 1335 1340 1345 1350 1355 1360 1365 1370 1375 1380 1385 1390 1395 1400 1405 1410 1415 1420 1425 1430 1435 1440 1445 1450 1455 1460 1465 1470 1475 1480 1485 1490 1495 1500 1505 1510 1515 1520 1525 1530 1535 1540 1545 1550 1555 1560 1565 1570 1575 1580 1585 1590 1595 1600 1605 1610 1615 1620 1625 1630 1635 1640 1645 1650 1655 1660 1665 1670 1675 1680 1685 1690 1695 1700 1705 1710 1715 1720 1725 1730 1735 1740 1745 1750 1755 1760 1765 1770 1775 1780 1785 1790 1795 1800 1805 1810 1815 1820 1825 1830 1835 1840 1845 1850 1855 1860 1865 1870 1875 1880 1885 1890 1895 1900 1905 1910 1915 1920 1925 1930 1935 1940 1945 1950 1955 1960 1965 1970 1975 1980 1985 1990 1995 2000 2005 2010 2015 2020 2025 2030 2035 2040 2045 2050 2055 2060 2065 2070 2075 2080 2085 2090 2095 2100 2105 2110 2115 2120 2125 2130 2135 2140 2145 2150 2155 2160 2165 2170 2175 2180 2185 2190 2195 2200 2205 2210 2215 2220 2225 2230 2235 2240 2245 2250 2255 2260 2265 2270 2275 2280 2285 2290 2295 2300 2305 2310 2315 2320 2325 2330 2335 2340 2345 2350 2355 2360 2365 2370 2375 2380 2385 2390 2395 2400 2405 2410 2415 2420 2425 2430 2435 2440 2445 2450 2455 2460 2465 2470 2475 2480 2485 2490 2495 2500 2505 2510 2515 2520 2525 2530 2535 2540 2545 2550 2555 2560 2565 2570 2575 2580 2585 2590 2595 2600 2605 2610 2615 2620 2625 2630 2635 2640 2645 2650 2655 2660 2665 2670 2675 2680 2685 2690 2695 2700 2705 2710 2715 2720 2725 2730 2735 2740 2745 2750 2755 2760 2765 2770 2775 2780 2785 2790 2795 2800 2805 2810 2815 2820 2825 2830 2835 2840 2845 2850 2855 2860 2865 2870 2875 2880 2885 2890 2895 2900 2905 2910 2915 2920 2925 2930 2935 2940 2945 2950 2955 2960 2965 2970 2975 2980 2985 2990 2995 3000 3005 3010 3015 3020 3025 3030 3035 3040 3045 3050 3055 3060 3065 3070 3075 3080 3085 3090 3095 3100 3105 3110 3115 3120 3125 3130 3135 3140 3145 3150 3155 3160 3165 3170 3175 3180 3185 3190 3195 3200 3205 3210 3215 3220 3225 3230 3235 3240 3245 3250 3255 3260 3265 3270 3275 3280 3285 3290 3295 3300 3305 3310 3315 3320 3325 3330 3335 3340 3345 3350 3355 3360 3365 3370 3375 3380 3385 3390 3395 3400 3405 3410 3415 3420 3425 3430 3435 3440 3445 3450 3455 3460 3465 3470 3475 3480 3485 3490 3495 3500 3505 3510 3515 3520 3525 3530 3535 3540 3545 3550 3555 3560 3565 3570 3575 3580 3585 3590 3595 3600 3605 3610 3615 3620 3625 3630 3635 3640 3645 3650 3655 3660 3665 3670 3675 3680 3685 3690 3695 3700 3705 3710 3715 3720 3725 3730 3735 3740 3745 3750 3755 3760 3765 3770 3775 3780 3785 3790 3795 3800 3805 3810 3815 3820 3825 3830 3835 3840 3845 3850 3855 3860 3865 3870 3875 3880 3885 3890 3895 3900 3905 3910 3915 3920 3925 3930 3935 3940 3945 3950 3955 3960 3965 3970 3975 3980 3985 3990 3995 4000 4005 4010 4015 4020 4025 4030 4035 4040 4045 4050 4055 4060 4065 4070 4075 4080 4085 4090 4095 4100 4105 4110 4115 4120 4125 4130 4135 4140 4145 4150 4155 4160 4165 4170 4175 4180 4185 4190 4195 4200 4205 4210 4215 4220 4225 4230 4235 4240 4245 4250 4255 4260 4265 4270 4275 4280 4285 4290 4295 4300 4305 4310 4315 4320 4325 4330 4335 4340 4345 4350 4355 4360 4365 4370 4375 4380 4385 4390 4395 4400 4405 4410 4415 4420 4425 4430 4435 4440 4445 4450 4455 4460 4465 4470 4475 4480 4485 4490 4495 4500 4505 4510 4515 4520 4525 4530 4535 4540 4545 4550 4555 4560 4565 4570 4575 4580 4585 4590 4595 4600 4605 4610 4615 4620 4625 4630 4635 4640 4645 4650 4655 4660 4665 4670 4675 4680 4685 4690 4695 4700 4705 4710 4715 4720 4725 4730 4735 4740 4745 4750 4755 4760 4765 4770 4775 4780 4785 4790 4795 4800 4805 4810 4815 4820 4825 4830 4835 4840 4845 4850 4855 4860 4865 4870 4875 4880 4885 4890 4895 4900 4905 4910 4915 4920 4925 4930 4935 4940 4945 4950 4955 4960 4965 4970 4975 4980 4985 4990 4995 5000 5005 5010 5015 5020 5025 5030 5035 5040 5045 5050 5055 5060 5065 5070 5075 5080 5085 5090 5095 5100 5105 5110 5115 5120 5125 5130 5135 5140 5145 5150 5155 5160 5165 5170 5175 5180 5185 5190 5195 5200 5205 5210 5215 5220 5225 5230 5235 5240 5245 5250 5255 5260 5265 5270 5275 5280 5285 5290 5295 5300 5305 5310 5315 5320 5325 5330 5335 5340 5345 5350 5355 5360 5365 5370 5375 5380 5385 5390 5395 5400 5405 5410 5415 5420 5425 5430 5435 5440 5445 5450 5455 5460 5465 5470 5475 5480 5485 5490 5495 5500 5505 5510 5515 5520 5525 5530 5535 5540 5545 5550 5555 5560 5565 5570 5575 5580 5585 5590 5595 5600 5605 5610 5615 5620 5625 5630 5635 5640 5645 5650 5655 5660 5665 5670 5675 5680 5685 5690 5695 5700 5705 5710 5715 5720 5725 5730 5735 5740 5745 5750 5755 5760 5765 5770 5775 5780 5785 5790 5795 5800 5805 5810 5815 5820 5825 5830 5835 5840 5845 5850 5855 5860 5865 5870 5875 5880 5885 5890 5895 5900 5905 5910 5915 5920 5925 5930 5935 5940 5945 5950 5955 5960 5965 5970 5975 5980 5985 5990 5995 6000 6005 6010 6015 6020 6025 6030 6035 6040 6045 6050 6055 6060 6065 6070 6075 6080 6085 6090 6095 6100 6105 6110 6115 6120 6125 6130 6135 6140 6145 6150 6155 6160 6165 6170 6175 6180 6185 6190 6195 6200 6205 6210 6215 6220 6225 6230 6235 6240 6245 6250 6255 6260 6265 6270 6275 6280 6285 6290 6295 6300 6305 6310 6315 6320 6325 6330 6335 6340 6345 6350 6355 6360 6365 6370 6375 6380 6385 6390 6395 6400 6405 6410 6415 6420 6425 6430 6435 6440 6445 6450 6455 6460 6465 6470 6475 6480 6485 6490 6495 6500 6505 6510 6515 6520 6525 6530 6535 6540 6545 6550 6555 6560 6565 6570 6575 6580 6585 6590 6595 6600 6605 6610 6615 6620 6625 6630 6635 6640 6645 6650 6655 6660 6665 6670 6675 6680 6685 6690 6695 6700 6705 6710 6715 6720 6725 6730 6735 6740 6745 6750 6755 6760 6765 6770 6775 6780 6785 6790 6795 6800 6805 6810 6815 6820 6825 6830 6835 6840 6845 6850 6855 6860 6865 6870 6875 6880 6885 6890 6895 6900 6905 6910 6915 6920 6925 6930 6935 6940 6945 6950 6955 6960 6965 6970 6975 6980 6985 6990 6995 7000 7005 7010 7015 7020 7025 7030 7035 7040 7045 7050 7055 7060 7065 7070 7075 7080 7085 7090 7095 7100 7105 7110 7115 7120 7125 7130 7135 7140 7145 7150 7155 7160 7165 7170 7175 7180 7185 7190 7195 7200 7205 7210 7215 7220 7225 7230 7235 7240 7245 7250 7255 7260 7265 7270 7275 7280 7285 7290 7295 7300 7305 7310 7315 7320 7325 7330 7335 7340 7345 7350 7355 7360 7365 7370 7375 7380 7385 7390 7395 7400 7405 7410 7415 7420 7425 7430 7435 7440 7445 7450 7455 7460 7465 7470 7475 7480 7485 7490 7495 7500 7505 7510 7515 7520 7525 7530 7535 7540 7545 7550 7555 7560 7565 7570 7575 7580 7585 7590 7595 7600 7605 7610 7615 7620 7625 7630 7635 7640 7645 7650 7655 7660 7665 7670 7675 7680 7685 7690 7695 7700 7705 7710 7715 7720 7725 7730 7735 7740 7745 7750 7755 7760 7765 7770 7775 7780 7785 7790 7795 7800 7805 7810 7815 7820 7825 7830 7835 7840 7845 7850 7855 7860 7865 7870 7875 7880 7885 7890 7895 7900 7905 7910 7915 7920 7925 7930 7935 7940 7945 7950 7955 7960 7965 7970 7975 7980 7985 7990 7995 8000 8005 8010 8015 8020 8025 8030 8035 8040 8045 8050 8055 8060 8065 8070 8075 8080 8085 8090 8095 8100 8105 8110 8115 8120 8125 8130 8135 8140 8145 8150 8155 8160 8165 8170 8175 8180 8185 8190 8195 8200 8205 8210 8215 8220 8225 8230 8235 8240 8245 8250 8255 8260 8265 8270 8275 8280 8285 8290 8295 8300 8305 8310 8315 8320 8325 8330 8335 8340 8345 8350 8355 8360 8365 8370 8375 8380 8385 8390 8395 8400 8405 8410 8415 8420 8425 8430 8435 8440 8445 8450 8455 8460 8465 8470 8475 8480 8485 8490 8495 8500 8505 8510 8515 8520 8525 8530 8535 8540 8545 8550 8555 8560 8565 8570 8575 8580 8585 8590 8595 8600 8605 8610 8615 8620 8625 8630 8635 8640 8645 8650 8655 8660 8665 8670 8675 8680 8685 8690 8695 8700 8705 8710 8715 8720 8725 8730 8735 8740 8745 8750 8755 8760 8765 8770 8775 8780 8785 8790 8795 8800 8805 8810 8815 8820 8825 8830 8835 8840 8845 8850 8855 8860 8865 8870 8875 8880 8885 8890 8895 8900 8905 8910 8915 8920 8925 8930 8935 8940 8945 8950 8955 8960 8965 8970 8975 8980 8985 8990 8995 9000 9005 9010 9015 9020 9025 9030 9035 9040 9045 9050 9055 9060 9065 9070 9075 9080 9085 9090 9095 9100 9105 9110 9115 9120 9125 9130 9135 9140 9145 9150 9155 9160 9165 9170 9175 9180 9185 9190 9195 9200 9205 9210 9215 9220 9225 9230 9235 9240 9245 9250 9255 9260 9265 9270 9275 9280 9285 9290 9295 9300 9305 9310 9315 9320 9325 9330 9335 9340 9345 9350 9355 9360 9365 9370 9375 9380 9385 9390 9395 9400 9405 9410 9415 9420 9425 9430 9435 9440 9445 9450 9455 9460 9465 9470 9475 9480 9485 9490 9495 9500 9505 9510 9515 9520 9525 9530 9535 9540 9545 9550 9555 9560 9565 9570 9575 9580 9585 9590 9595 9600 9605 9610 9615 9620 9625 9630 9635 9640 9645 9650 9655 9660 9665 9670 9675 9680 9685 9690 9695 9700 9705 9710 9715 9720 9725 9730 9735 9740 9745 9750 9755 9760 9765 9770 9775 9780 9785 9790 9795 9800 9805 9810 9815 9820 9825 9830 9835 9840 9845 9850 9855 9860 9865 9870 9875 9880 9885 9890 9895 9900 9905 9910 9915 9920 9925 9930 9935 9940 9945 9950 9955 9960 9965 9970 9975 9980 9985 9990 9995 9999

55

65